<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67290</article-id><article-id pub-id-type="doi">10.7554/eLife.67290</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Role of the transcriptional regulator SP140 in resistance to bacterial infections via repression of type I interferons</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-225472"><name><surname>Ji</surname><given-names>Daisy X</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9148-3620</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">‚Ä†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-225473"><name><surname>Witt</surname><given-names>Kristen C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8744-9457</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">‚Ä†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225474"><name><surname>Kotov</surname><given-names>Dmitri I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7843-1503</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225475"><name><surname>Margolis</surname><given-names>Shally R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225476"><name><surname>Louie</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225477"><name><surname>Chev√©e</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225478"><name><surname>Chen</surname><given-names>Katherine J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192779"><name><surname>Gaidt</surname><given-names>Moritz M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225479"><name><surname>Dhaliwal</surname><given-names>Harmandeep S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188410"><name><surname>Lee</surname><given-names>Angus Y</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-14853"><name><surname>Nishimura</surname><given-names>Stephen L</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80262"><name><surname>Zamboni</surname><given-names>Dario S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7856-7512</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55759"><name><surname>Kramnik</surname><given-names>Igor</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6511-9246</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150241"><name><surname>Portnoy</surname><given-names>Daniel A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225484"><name><surname>Darwin</surname><given-names>K Heran</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-44759"><name><surname>Vance</surname><given-names>Russell E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6686-3912</contrib-id><email>rvance@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Cancer Research Laboratory, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Pathology, University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Cell Biology, Ribeir√£o Preto Medical School, University of S√£o Paulo</institution><addr-line><named-content content-type="city">S√£o Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff6"><label>6</label><institution>The National Emerging Infectious Diseases Laboratory, Department of Medicine (Pulmonary Center), and Department of Microbiology, Boston University School of Medicine</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Division of Biochemistry, Biophysics and Structural Biology, Department of Molecular and Cell Biology, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Plant and Microbial Biology, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Department of Microbiology, New York University Grossman School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Stallings</surname><given-names>Christina L</given-names></name><role>Reviewing Editor</role><aff><institution>Washington University School of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution>Indian Institute of Science Education and Research (IISER)</institution><country>India</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>‚Ä†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>21</day><month>06</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67290</elocation-id><history><date date-type="received" iso-8601-date="2021-02-06"><day>06</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-20"><day>20</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>¬© 2021, Ji et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Ji et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67290-v2.pdf"/><abstract><p>Type I interferons (IFNs) are essential for anti-viral immunity, but often impair protective immune responses during bacterial infections. An important question is how type I IFNs are strongly induced during viral infections, and yet are appropriately restrained during bacterial infections. The <italic>Super susceptibility to tuberculosis 1</italic> (<italic>Sst1</italic>) locus in mice confers resistance to diverse bacterial infections. Here we provide evidence that <italic>Sp140</italic> is a gene encoded within the <italic>Sst1</italic> locus that represses type I IFN transcription during bacterial infections. We generated <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice and found that they are susceptible to infection by <italic>Legionella pneumophila</italic> and <italic>Mycobacterium tuberculosis</italic>. Susceptibility of <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice to bacterial infection was rescued by crosses to mice lacking the type I IFN receptor (<italic>Ifnar</italic><sup>‚Äì/‚Äì</sup>). Our results implicate <italic>Sp140</italic> as an important negative regulator of type I IFNs that is essential for resistance to bacterial infections.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mycobacterium tuberculosis</kwd><kwd>legionella pneumophila</kwd><kwd>type i interferon</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R37AI075039</award-id><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI155634</award-id><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Investigator Award</award-id><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01AI066302</award-id><principal-award-recipient><name><surname>Portnoy</surname><given-names>Daniel A</given-names></name><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01HL134183</award-id><principal-award-recipient><name><surname>Nishimura</surname><given-names>Stephen L</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000861</institution-id><institution>Burroughs Wellcome Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name><name><surname>Darwin</surname><given-names>K Heran</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Repression of type I interferons by SP140 is essential for resistance to <italic>Legionella pneumophila</italic> and <italic>Mycobacterium tuberculosis</italic>.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Type I interferons (IFNs) comprise a group of cytokines, including interferon-Œ≤ and multiple interferon-Œ± isoforms, that are essential for immune defense against most viruses (<xref ref-type="bibr" rid="bib52">Stetson and Medzhitov, 2006</xref>). Type I IFNs signal through a cell surface receptor, the interferon alpha and beta receptor (IFNAR), to induce an ‚Äòanti-viral state‚Äô that is characterized by the transcriptional induction of hundreds of interferon-stimulated genes (ISGs) (<xref ref-type="bibr" rid="bib49">Schneider et al., 2014</xref>). Many ISGs encode proteins with direct anti-viral activities. Type I IFNs also promote anti-viral responses by cytotoxic T cells and natural killer cells. Accordingly, <italic>Ifnar</italic><sup>‚Äì/‚Äì</sup> mice are highly susceptible to most viral infections.</p><p>Many ISGs are also induced by IFN-Œ≥ (also called type II IFN). However, type I and type II IFNs appear to be specialized for the control of different classes of pathogens (<xref ref-type="bibr" rid="bib10">Crisler and Lenz, 2018</xref>). Whereas type I IFNs are predominantly anti-viral, the ISGs induced by IFN-Œ≥ appear to be especially important for the control of diverse intracellular pathogens, including parasites and bacteria. In contrast, type I IFNs play complex roles during bacterial infections (<xref ref-type="bibr" rid="bib5">Boxx and Cheng, 2016</xref>; <xref ref-type="bibr" rid="bib12">Donovan et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">McNab et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Moreira-Teixeira et al., 2018</xref>). Some ISGs induced by type I IFN, most notably certain guanylate-binding proteins (GBPs), have anti-bacterial activities (<xref ref-type="bibr" rid="bib41">Pilla-Moffett et al., 2016</xref>). At the same time, other proteins induced by type I IFNs, including interleukin-10 (IL-10) and IL-1 receptor antagonist (IL-1RA), impair anti-bacterial immunity (<xref ref-type="bibr" rid="bib5">Boxx and Cheng, 2016</xref>; <xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Mayer-Barber et al., 2014</xref>). As a result, the net effect of type I IFN is often to increase susceptibility to bacterial infections. For example, <italic>Ifnar</italic><sup>‚Äì/‚Äì</sup> mice exhibit enhanced resistance to <italic>Listeria monocytogenes</italic> (<xref ref-type="bibr" rid="bib2">Auerbuch et al., 2004</xref>; <xref ref-type="bibr" rid="bib8">Carrero et al., 2004</xref>; <xref ref-type="bibr" rid="bib37">O'Connell et al., 2004</xref>) and <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="bibr" rid="bib12">Donovan et al., 2017</xref>; <xref ref-type="bibr" rid="bib13">Dorhoi et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Mayer-Barber et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Moreira-Teixeira et al., 2018</xref>). Multiple mechanisms appear to explain resistance of <italic>Ifnar</italic><sup>‚Äì/‚Äì</sup> mice to <italic>L. monocytogenes</italic>, including a negative effect of type I IFNs on protective IFN-Œ≥ signaling (<xref ref-type="bibr" rid="bib45">Rayamajhi et al., 2010</xref>). Likewise, diverse mechanisms underlie the negative effects of type I IFNs during <italic>M. tuberculosis</italic> infection, including alterations of eicosanoid production (<xref ref-type="bibr" rid="bib33">Mayer-Barber et al., 2014</xref>) and the induction of IL-1Ra (<xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>), both of which impair protective IL-1 responses.</p><p>As an experimental model for dissecting the mechanisms by which inappropriate type I IFN responses are restrained during bacterial infections, we have compared mice harboring different haplotypes of the <italic>Super susceptibility to tuberculosis 1</italic> (<italic>Sst1</italic>) locus (<xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>; <xref ref-type="bibr" rid="bib40">Pichugin et al., 2009</xref>). The <italic>Sst1</italic> locus encompasses about 10M base pairs of mouse chromosome 1, a region that contains approximately 50 genes. Mice harboring the susceptible (S) haplotype of <italic>Sst1</italic>, derived from the C3H/HeBFeJ mouse strain, succumb relatively rapidly to <italic>M. tuberculosis</italic> infection as compared to isogenic mice harboring the resistant (R) <italic>Sst1</italic> haplotype (derived from C57BL/6 mice). Likewise, <italic>Sst1<sup>S</sup></italic> mice also exhibit enhanced susceptibility to <italic>L. monocytogenes</italic> (<xref ref-type="bibr" rid="bib6">Boyartchuk et al., 2004</xref>; <xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>) and <italic>Chlamydia pneumoniae</italic> (<xref ref-type="bibr" rid="bib19">He et al., 2013</xref>). The susceptibility of <italic>Sst1<sup>S</sup></italic> mice to <italic>M. tuberculosis</italic> was reversed by crossing to <italic>Ifnar</italic><sup>‚Äì/‚Äì</sup> mice (<xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>), thereby demonstrating the causative role of type I IFNs in driving the susceptibility phenotype. Although multiple type I IFN-induced genes are likely responsible for the detrimental effects of type I IFNs during bacterial infections, heterozygous deficiency of a single type I IFN-induced gene, <italic>Il1rn</italic> (encoding IL-1 receptor antagonist), was sufficient to almost entirely reverse the susceptibility of <italic>Sst1<sup>S</sup></italic> mice to <italic>M. tuberculosis</italic> (<xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>).</p><p>The <italic>Sst1<sup>R</sup></italic> haplotype is dominant over the <italic>Sst1<sup>S</sup></italic> haplotype, suggesting that <italic>Sst1<sup>R</sup></italic> encodes a protective factor that is absent from <italic>Sst1<sup>S</sup></italic> mice (<xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>; <xref ref-type="bibr" rid="bib40">Pichugin et al., 2009</xref>). By comparing gene expression in <italic>Sst1<sup>R</sup></italic> versus <italic>Sst1<sup>S</sup></italic> mice, <italic>Sp110</italic> (also known as <italic>Ipr1</italic>) was discovered as an <italic>Sst1</italic>-encoded gene that is transcribed selectively in <italic>Sst1<sup>R</sup></italic> mice (<xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>). Transgenic expression of <italic>Sp110</italic> in <italic>Sst1<sup>S</sup></italic> mice partially restored resistance to <italic>M. tuberculosis</italic> and <italic>L. monocytogenes</italic> (<xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>). However, the causative role of <italic>Sp110</italic> in conferring resistance to bacterial infections was not confirmed by the generation of <italic>Sp110</italic>-deficient B6 mice. Null mutations of human <italic>SP110</italic> are associated with VODI (hepatic veno-occlusive disease with immunodeficiency syndrome, OMIM 235550), but not mycobacterial diseases (<xref ref-type="bibr" rid="bib46">Roscioli et al., 2006</xref>). Some studies have found polymorphisms in <italic>SP110</italic> to be associated with susceptibility to TB, though not consistently so across different ethnic groups (<xref ref-type="bibr" rid="bib9">Chang et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Fox et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Lei et al., 2012</xref>; <xref ref-type="bibr" rid="bib43">Png et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Thye et al., 2006</xref>; <xref ref-type="bibr" rid="bib54">Tosh et al., 2006</xref>; <xref ref-type="bibr" rid="bib57">Zhang et al., 2017</xref>).</p><p>In humans and mice, SP110 is a part of the speckled protein (SP) family of nuclear proteins, consisting of SP100, SP110, and SP140 (and SP140L in humans only) (<xref ref-type="bibr" rid="bib16">Fraschilla and Jeffrey, 2020</xref>). The SP family members also exhibit a high degree of similarity to AIRE, a transcriptional regulator that promotes tolerance to self-antigens by inducing their expression in thymic epithelial cells (<xref ref-type="bibr" rid="bib1">Anderson and Su, 2016</xref>; <xref ref-type="bibr" rid="bib16">Fraschilla and Jeffrey, 2020</xref>; <xref ref-type="bibr" rid="bib39">Perniola and Musco, 2014</xref>). All members of the SP-AIRE family in both mice and humans have an N-terminal SP100 domain that appears to function as a homotypic protein-protein interaction domain (<xref ref-type="bibr" rid="bib16">Fraschilla and Jeffrey, 2020</xref>; <xref ref-type="bibr" rid="bib20">Huoh et al., 2020</xref>). The SP100 domain is closely related to the caspase activation and recruitment domain (CARD), though SP family members are not believed to activate caspases. SP-AIRE proteins also contain a DNA-binding SAND domain (<xref ref-type="bibr" rid="bib4">Bottomley et al., 2001</xref>). Certain SP isoforms, including all human full-length SP family members and mouse SP140, also include a plant homeobox domain (PHD) and a bromodomain (BRD) (<xref ref-type="bibr" rid="bib16">Fraschilla and Jeffrey, 2020</xref>). The genes encoding SP family proteins are linked in a small cluster in both mouse and human genomes and are inducible by IFN-Œ≥ in a variety of cell lines. The mouse <italic>Sp100/110/140</italic> gene cluster is adjacent to a highly repetitive ‚Äòhomogenously staining region‚Äô (HSR) of chromosome 1 that remains poorly assembled in the most recent genome assembly due to the presence of as many as 40 near-identical repeats of <italic>Sp110</italic>-like sequences (<xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>; <xref ref-type="bibr" rid="bib56">Weichenhan et al., 2001</xref>). Most of these repeated <italic>Sp110</italic>-like sequences in the HSR appear to be either incomplete copies of <italic>Sp110</italic> or pseudogenes that are not believed to be translated, but their presence has nevertheless complicated genetic targeting and analysis of the SP gene family.</p><p>With the advent of CRISPR/Cas9-based methods (<xref ref-type="bibr" rid="bib55">Wang et al., 2013</xref>), we were able to generate <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice on the B6 background. Surprisingly, we found that <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice do not phenocopy the susceptibility of <italic>Sst1<sup>S</sup></italic> mice to <italic>M. tuberculosis</italic> infection in vivo. Upon analysis of additional candidate genes in the <italic>Sst1</italic> locus, we found that B6.<italic>Sst1<sup>S</sup></italic> mice also lack expression of <italic>Sp140</italic>. To test whether loss of <italic>Sp140</italic> might account for the susceptibility of <italic>Sst1<sup>S</sup></italic> mice to bacterial infections, we generated <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice. We found that¬†these mice are as susceptible as B6.<italic>Sst1<sup>S</sup></italic> mice to the intracellular bacterial pathogens <italic>M. tuberculosis</italic> and <italic>Legionella pneumophila</italic>. Similar to B6.<italic>Sst1<sup>S</sup></italic> mice, <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice exhibit an exacerbated type I IFN response after bacterial infection, and the susceptibility of <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice is rescued by crosses to <italic>Ifnar</italic><sup>‚Äì/‚Äì</sup> mice. Our results suggest that loss of <italic>Sp140</italic> explains the susceptibility to bacterial infections associated with the <italic>Sst1<sup>S</sup></italic> haplotype. These data further suggest that SP140 is a novel negative regulator of type I IFN responses that is essential for protection against intracellular bacterial infections.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice are not susceptible to <italic>M. tuberculosis</italic></title><p>Loss of <italic>Sp110</italic> expression was proposed to account for the susceptibility of mice carrying the <italic>Sst1<sup>S</sup></italic> haplotype to bacterial infections (<xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>). We first confirmed that bone marrow-derived macrophages (BMMs) from B6.<italic>Sst1<sup>S</sup></italic> mice lack expression of <italic>Sp110</italic> protein (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To determine whether loss of <italic>Sp110</italic> confers susceptibility to bacterial infections, we used CRISPR/Cas9 to target exon 3 of <italic>Sp110</italic> to generate <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice on the C57BL/6 (B6) background (<xref ref-type="fig" rid="fig1s1">Figure 1‚Äîfigure supplement 1</xref>). We generated three independent <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> lines, denoted as lines 61, 65, and 71 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1‚Äîfigure supplement 1</xref>). All three lines lacked expression of <italic>Sp110</italic>, as verified using three different antibodies (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice are viable and are born at normal Mendelian ratios and litter sizes. When aerosol infected with a low¬†dose of <italic>M. tuberculosis</italic>, <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice did not phenocopy the susceptibility observed in B6.<italic>Sst1<sup>S</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1B-D</xref>). At day 25 post-infection, <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> lungs resembled those of wild-type B6 mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) and harbored fewer bacteria than the lungs of B6.<italic>Sst1<sup>S</sup></italic> mice, similar to both the B6 and <italic>Sp110<sup>+/‚Äì</sup></italic> littermates (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Likewise, the survival of infected <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice was indistinguishable from B6 mice, and mice of both genotypes survived considerably longer than the B6.<italic>Sst1<sup>S</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Thus, despite the absence of <italic>Sp110</italic> from <italic>Sst1<sup>S</sup></italic> mice, our results indicate that the loss of <italic>Sp110</italic> is not sufficient to replicate the susceptibility to <italic>M. tuberculosis</italic> associated with the <italic>Sst1<sup>S</sup></italic> locus.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice are not susceptible to <italic>Mycobacterium¬†tuberculosis</italic> infections.</title><p>(<bold>A</bold>) BMMs were treated with 10 U/ml of IFNŒ≥ for 24 hr and cells were lysed with RIPA buffer. Five micrograms of total protein was loaded on each lane, and immunoblot was performed with respective antibodies as shown. Molecular weight standards are shown on the left of each blot in kDa. Individual membranes were imaged separately. Three independent lines of <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> mice were analyzed (denoted lines 61, 65, and 71). (<bold>B‚ÄìD</bold>) Lungs of mice infected with <italic>M. tuberculosis</italic> were stained with hematoxylin and eosin (H&amp;E) for histology (<bold>B</bold>), measured for CFU at 25 days post-infection (Mann-Whitney test) (<bold>C</bold>), or monitored for survival (<bold>D</bold>). All except B6 mice were bred in-house, and combined results from the three independent <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> lines are shown. Representative of two experiments (<bold>B, D</bold>); combined results of three infections (<bold>C</bold>). *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005.¬†BMM, bone marrow-derived macrophage;¬†CFU, colony-forming unit;¬†RIPA,¬†radioimmunoprecipitation assay.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1‚Äîfigure supplement 1.</label><caption><title>CRISPR/Cas9 targeting strategy for <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice.</title><p>(<bold>A</bold>) Mouse <italic>Sp110</italic> gene. Guide RNA sequence for CRISPR/Cas9 targeting and protospacer-adjacent motif (PAM) are indicated. (<bold>B‚ÄìD</bold>) <italic>Sp110</italic> locus in wild-type (WT) and three independent lines. Homozygotes of two lines identified by sequencing (<bold>B,¬†C</bold>), and heterozygote of the third line by PCR products separated on an agarose gel (<bold>D</bold>). Arrow indicates the mutant band.¬†PCR,¬†polymerase chain reaction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice are susceptible to bacterial infections</title><p>Given that <italic>Sp110</italic> deficiency did not phenocopy the susceptibility of <italic>Sst1<sup>S</sup></italic> mice, we asked whether any other genes found within the <italic>Sst1</italic> locus differ in expression between B6 and B6.<italic>Sst1<sup>S</sup></italic> BMMs. We noted that a homolog of <italic>Sp110</italic> called <italic>Sp140</italic> was also reduced in expression in B6.<italic>Sst1<sup>S</sup></italic> cells compared to B6 cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Immunoblot confirmed that IFN-Œ≥ treated BMMs from B6.<italic>Sst1<sup>S</sup></italic> mice do not produce SP140 protein (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). We therefore used CRISPR/Cas9 to generate two independent lines of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice on a pure B6 background (<xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1A-C</xref>). Our analysis focused primarily on line 1, which we found lacked expression of SP140 protein (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) but retains the production of SP110 protein (<xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1D</xref>). Like <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> and <italic>Sst1<sup>S</sup></italic> mice, <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice are viable, fertile, and born at the expected Mendelian ratios. When infected with <italic>M. tuberculosis</italic>, however, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice exhibited high bacterial burdens in their lungs, similar to B6.<italic>Sst1<sup>S</sup></italic> mice and significantly greater than B6, <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> or <italic>Sp140<sup>+/‚Äì</sup></italic> littermate mice at day 28 post-infection (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1D</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice are susceptible to bacterial pathogens.</title><p>(<bold>A</bold>) RT-PCR of cDNA from BMMs of the indicated genotypes. Red arrow indicates band corresponding to a portion of <italic>Sp140</italic>, verified by sequencing. (<bold>B</bold>) Immunoblot of lysates from <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6 BMMs treated with 10 U/ml of recombinant mouse IFNŒ≥ for 24 hr. Equal amounts of protein were loaded for immunoblot with anti-SP140 antibody. (<bold>C‚ÄìF</bold>) Mice were infected with <italic>Mycobacterium¬†tuberculosis</italic> and measured for (<bold>C</bold>) lung CFU at 28 days post-infection, (<bold>E</bold>) body weight over time, and (<bold>F</bold>) survival. Statistics in (<bold>E</bold>) shows the¬†comparison to B6 at day 28, and data are from 10 B6, 11 B6.<italic>Sst1<sup>S</sup></italic>, 11 <italic>Sp110</italic><sup>‚Äì/‚Äì</sup>, 14 <italic>Sp140</italic><sup>‚Äì/‚Äì</sup>, and 6 <italic>Sp140</italic><sup>+/‚Äì</sup>mice. (<bold>D</bold>) H&amp;E staining of lungs at 25 days post-infection with <italic>M. tuberculosis</italic>. Full histology images are provided in <xref ref-type="fig" rid="fig2s2">Figure 2‚Äîfigure supplement 2</xref>. (<bold>G</bold>) Mice were infected with <italic>Legionella pneumophila</italic> and lung CFUs were determined at 96 hr post-infection. All mice were bred in-house, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and <italic>Sp140<sup>+/‚Äì</sup></italic> were littermates (<bold>C‚ÄìF</bold>). (<bold>C</bold>), (<bold>E</bold>), and (<bold>G</bold>) are combined results of two independent infections. (<bold>A‚ÄìD</bold>) show representative analysis of one <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> line (line 1), whereas (<bold>F,¬†G</bold>) include a mixture of both lines 1 and 2. Results of infection of both lines with <italic>M. tuberculosis</italic> are shown in <xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1E</xref>. (<bold>C, E, F, G</bold>) Mann-Whitney test. *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005.¬†BMM, bone marrow-derived macrophage;¬†CFU, colony-forming unit;¬†H&amp;E, hematoxylin and eosin;¬†RT-qPCR, real-time quantitative-polymerase chain reaction;¬†WT, wild-type.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2‚Äîfigure supplement 1.</label><caption><title>CRISPR/Cas9 targeting strategy for <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and validation of founders.</title><p>(<bold>A</bold>) Mouse <italic>Sp140</italic> gene. Guide RNA sequence for CRISPR/Cas9 targeting and protospacer-adjacent motif (PAM) are indicated. (<bold>B,¬†C</bold>) <italic>Sp140</italic> locus in wild-type (WT) and two independent founders of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> validated by sequencing. (<bold>D</bold>) Immunoblot for SP110 using BMMs from mice of the indicated genotypes. Intervening lanes have been removed for clarity (indicated by line in the image). (<bold>E</bold>) <italic>Mycobacterium¬†tuberculosis</italic>-infected mice were harvested for CFU at 25 days post-infection. Empty and filled triangles indicate the two independent lines of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> used in this infection. All mice were bred in-house and <italic>Sp140<sup>+/‚Äì</sup></italic>¬†¬± littermates with <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> line 2. Mann-Whitney test. *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005.¬†BMM, bone marrow-derived macrophage;¬†CFU, colony-forming unit.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2‚Äîfigure supplement 2.</label><caption><title>Histology of lungs from B6, B6.<italic>Sst1<sup>S</sup></italic>, <italic>Sp110<sup>‚Äì/‚Äì</sup></italic>, and¬†<italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice after infection with <italic>Mycobacterium¬†tuberculosis.</italic></title><p>H&amp;E staining of entire lung sections from mice of indicated genotypes at 25 days post-infection with <italic>M. tuberculosis.</italic> Black squares denote sections shown in <xref ref-type="fig" rid="fig2">Figure 2C</xref>. Each image represents a lung section from a different mouse. Borders in background color have been added around each image. Scale bar applies to all images. Samples were evaluated and scored (0‚Äì4, least to most) for macrophage (histocyte), lymphoid, granulocyte infiltration, and extent of necrosis.¬†H&amp;E, hematoxylin and eosin.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2‚Äîfigure supplement 3.</label><caption><title>Characterization of off-target genes mutated in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice.</title><p>(<bold>A</bold>) Schematic of amplicon sequencing strategy for <italic>Sp140</italic> and <italic>Sp140</italic> homologs. (<bold>B</bold>) Summary of edited <italic>Sp140</italic> homologs from amplicon sequencing and RNA-seq analysis. SNPs are denoted based on the <italic>Sp140</italic> X1 transcript. Expression level was roughly estimated from read counts. Three B6 and two <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice from each founder line were used as biological replicates for <italic>Sp140</italic> exon 2/3 amplicon sequencing from cDNA, two mice per genotype were used for <italic>Sp140</italic> exon 3 amplicon sequencing from cDNA, and one mouse per genotype was used for <italic>Sp140</italic> exon 3 amplicon sequencing from DNA.¬†SNP, single-nucleotide polymorphism.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2‚Äîfigure supplement 4.</label><caption><title>Complementation of hyper type I IFN responses in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs.</title><p>(<bold>A</bold>) BMMs were left untreated or treated with TNF-Œ± for 24 hr. Total RNA was used for RT-qPCR. Averages of technical duplicates for one biological replicate are shown. Data is representative of two independent experiments. (<bold>B</bold>) RT-qPCR of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs transduced with either control SINV-minCMV-GAL4-mNeonGreen (SINV-mNeonGreen) or SINV-minCMV-Sp140 (SINV-Sp140), primed with 5 ng/mL IFN-ùõæ for 14 hr and treated with 10 ng/mL TNF-‚ç∫ for 4 hr. *p‚â§0.05 calculated with an unpaired <italic>t</italic>-test with Welch‚Äôs correction. Data are representative of two independent experiments.¬†BMM, bone marrow-derived macrophage;¬†RT-qPCR, real-time quantitative-polymerase chain reaction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig2-figsupp4-v2.tif"/></fig></fig-group><p>We performed hematoxylin and eosin (H&amp;E) staining of lung sections from B6, <italic>Sp140</italic><sup>‚Äì/‚Äì</sup>, <italic>Sp110</italic><sup>‚Äì/‚Äì</sup>, and B6.<italic>Sst1<sup>S</sup></italic> mice 25 days after <italic>M. tuberculosis</italic> infection, and qualitatively assessed macrophage, lymphoid, and granulocyte infiltration as well as the extent of necrosis (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2‚Äîfigure supplement 2</xref>). We found that <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> and B6.<italic>Sst1<sup>S</sup></italic> lungs showed moderately increased granulocyte infiltration by 25 days post infection, with apparently more severe infiltration in <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice than in B6.<italic>Sst1<sup>S</sup></italic> mice, though this difference is not statistically significant. We could also discern some areas of necrosis in the <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> lungs, although our samples were taken at an early timepoint that precedes the formation of hypoxic lesions observed in B6.<italic>Sst1<sup>S</sup></italic> lungs upon <italic>M. tuberculosis</italic> infection (<xref ref-type="bibr" rid="bib18">Harper et al., 2012</xref>). The increased susceptibility of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice was accompanied by significant weight loss and shortened survival upon infection with <italic>M. tuberculosis</italic>, again phenocopying the B6.<italic>Sst1<sup>S</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2E-F</xref>). Both of the independent lines of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice were similarly susceptible to <italic>M. tuberculosis</italic> (<xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1E</xref>). We also found that both B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice were more susceptible to the intracellular Gram-negative bacterium <italic>L. pneumophila</italic>, as compared to the B6 and <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2G</xref>).</p><p>An important caveat to the use of CRISPR/Cas9 to generate <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice is the presence of an unknown number of nearly identical <italic>Sp140</italic>-like genes in the <italic>Sst1</italic> locus and non-localized chromosome 1 genome contigs (that presumably map to the adjacent HSR that remains unassembled by the mouse genome project). It is possible that the guide RNA we used to disrupt exon 3 of <italic>Sp140</italic> also disrupted these uncharacterized <italic>Sp140</italic>-like genes, though it is not clear if these uncharacterized <italic>Sp140</italic>-like genes give rise to functional proteins. Nevertheless, to identify potential mutated off-target genes in our <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice, we amplified exons 2/3 of <italic>Sp140</italic> and any potential paralogs from genomic DNA and from cDNA derived from <italic>M. tuberculosis-</italic>infected lungs, and subjected the amplicons to deep sequencing (<xref ref-type="fig" rid="fig2s3">Figure 2‚Äîfigure supplement 3</xref>). Although we found evidence for several edited <italic>Sp140</italic>-like exons in our <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice, only one of these edited off-target genes was found to be detectably expressed from analysis of RNA-seq data from <italic>M. tuberculosis-</italic>infected lungs, and this off-target appeared to be edited in only one of our founder lines (<xref ref-type="fig" rid="fig2s3">Figure 2‚Äîfigure supplement 3B</xref>). Thus, mutation of <italic>Sp140</italic> itself is the most parsimonious explanation for susceptibility of our <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice, a conclusion further supported by complementation of the mutation in BMMs (see below, <xref ref-type="fig" rid="fig2s4">Figure 2‚Äîfigure supplement 4</xref>). Collectively our results strongly suggest that the lack of expression of <italic>Sp140</italic> in B6.<italic>Sst1<sup>S</sup></italic> mice explains the broad susceptibility of these mice to bacterial infections.</p></sec><sec id="s2-3"><title>Enhanced type I IFN responses in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> mice</title><p>We and others previously reported that TNFŒ± induces higher levels of type I IFN-induced genes in <italic>Sst1<sup>S</sup></italic> BMMs as compared to B6 BMMs (<xref ref-type="bibr" rid="bib3">Bhattacharya et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>). We also observed higher levels of <italic>Ifnb</italic> transcripts in the lungs of B6.<italic>Sst1<sup>S</sup></italic> mice infected with <italic>M. tuberculosis</italic>, as compared to infected B6 mice (<xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>). Similar to B6.<italic>Sst1<sup>S</sup></italic> BMMs, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs also exhibited elevated expression of <italic>Ifnb</italic> and ISGs when stimulated with TNFŒ± (<xref ref-type="fig" rid="fig2s4">Figure 2‚Äîfigure supplement 4A</xref>). Importantly, we were also able to complement the enhanced IFN phenotype of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs by transducing <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs with a retrovirus expressing an <italic>Sp140</italic> cDNA driven by a minimal CMV promoter (<xref ref-type="fig" rid="fig2s4">Figure 2‚Äîfigure supplement 4B</xref>). Repression of <italic>Ifnb</italic> by overexpression of <italic>Sp140</italic> in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs was selective, as <italic>Sp140</italic> overexpression did not repress the transcription of <italic>Tnfa</italic> induced by TNFŒ± (<xref ref-type="fig" rid="fig2s4">Figure 2‚Äîfigure supplement 4B</xref>).</p><p>In addition to enhanced type I IFN responses to TNFŒ±, we also observed that both B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs show increased cell death in vitro upon stimulation with polyI:C compared to B6 BMMs, as measured by lactate dehydrogenase (LDH) release (<xref ref-type="fig" rid="fig3s1">Figure 3‚Äîfigure supplement 1</xref>). This result is analogous to previous findings that B6.<italic>Sst1<sup>S</sup></italic> BMMs die upon sustained TNF stimulation (<xref ref-type="bibr" rid="bib7">Brownhill et al., 2020</xref>). The enhanced polyI:C-induced LDH release in both <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> and B6.<italic>Sst1<sup>S</sup></italic> BMMs was blunted upon genetic deletion of <italic>Ifnar</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3‚Äîfigure supplement 1</xref>), consistent with type I IFNs playing an important role in the cell death phenotype.</p><p>When infected with <italic>M. tuberculosis</italic>, the lungs of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> mice also exhibited higher levels of <italic>Ifnb</italic> transcript as compared to B6, <italic>Sp110<sup>‚Äì/‚Äì</sup></italic>,¬†and <italic>Sp140<sup>+/‚Äì</sup></italic>¬†littermate mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The lungs of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> exhibited moderately increased levels of <italic>Ifnb</italic> transcript compared to B6.<italic>Sst1<sup>S</sup></italic> during <italic>M. tuberculosis</italic> infection, which could be a result of partial low expression of <italic>Sp140</italic> in B6.<italic>Sst1<sup>S</sup></italic> mice, or possibly microbiota differences between the strains. Since we do not observe significant differences in weight, survival, or colony-forming unit¬†(CFU) between <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> mice upon <italic>M. tuberculosis</italic> infection, there is no evidence that modest differences in type I IFN responses are of functional significance. We also found that during <italic>L. pneumophila</italic> infection, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice expressed more <italic>Ifnb</italic> in their lungs, as compared to B6 mice (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Importantly, elevated <italic>Ifnb</italic> was evident at 48 hr post-infection when there is no difference in bacterial burdens between the genotypes, and at 96 hr post-infection, when <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice have greater bacterial burdens (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice have elevated <italic>Ifnb</italic> transcripts during bacterial infection.</title><p>(<bold>A</bold>) Mice were infected with <italic>Mycobacterium¬†tuberculosis</italic> and at 28 days post-infection, lungs were processed for total RNA, which was used for RT-qPCR. Combined results of two independent experiments. (<bold>B</bold>) Mice were infected with <italic>Legionella¬†pneumophila</italic> and RT-qPCR (top panel) and CFU enumeration (bottom panel) was performed on lungs collected at indicated times. Combined results of two independent infections. All mice were bred in-house, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and <italic>Sp140<sup>+/‚Äì</sup></italic>¬†were littermates. (<bold>A,¬†B</bold>) Mann-Whitney test. *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005.¬†CFU, colony-forming unit;¬†RT-qPCR, real-time quantitative-polymerase chain reaction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3‚Äîfigure supplement 1.</label><caption><title>BMMs from B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice show increased cell death upon stimulation with polyI:C, which is dependent upon IFNAR signaling.</title><p>LDH release from primary BMMs after 16‚Äì24 hr stimulation with 100 Œºg/mL polyI:C for (<bold>A</bold>) B6, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic>, B6.<italic>Sst1<sup>S</sup></italic>, and B6.<italic>Sst1<sup>S¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> mice. Results are technical duplicates, and representative of three independent experiments for B6 (three mice), B6.<italic>Sst1<sup>S</sup></italic> (two mice), and <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> (two mice) samples and two independent experiments for B6.<italic>Sst1<sup>S¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> sample (one mouse). (<bold>B</bold>) LDH release after polyI:C stimulation for primary BMMs from B6, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic>, and <italic>Sp140<sup>‚Äì/‚Äì¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> mice. Results represent technical triplicates and are representative of two independent experiments for two mice per genotype. * p‚â§0.05; **p‚â§0.01; ***p‚â§0.005 as calculated with an unpaired <italic>t</italic>-test with Welch‚Äôs correction.¬†BMM, bone marrow-derived macrophage;¬†IFNAR, interferon alpha and beta receptor;¬†LDH, lactate dehydrogenase.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Infected <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> lungs show similar gene expression patterns</title><p>We used RNA sequencing to analyze the global gene expression patterns in <italic>M. tuberculosis-</italic>infected lungs of B6, <italic>Sp110</italic><sup>‚Äì/‚Äì</sup>, <italic>Sp140</italic><sup>‚Äì/‚Äì</sup>,¬†and B6.<italic>Sst1<sup>S</sup></italic> mice at day 28 post-infection (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Principal component analysis revealed that while there is spread among individual samples, the expression pattern of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> lungs segregates from the expression pattern in B6 and <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> lungs along the PC1 axis (77% of variance) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Notably, the <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> only separated along the PC2 axis, which accounts for only 9% of the variance in our RNA-seq data. Euclidean distance analysis revealed a similar pattern, with B6.<italic>Sst1</italic><sup>S</sup> and <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice clustering together, and away from B6 and <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). At the time point analyzed (28 dpi), both <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> mice exhibit higher bacterial burdens than B6 and <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Thus, the similarity of the gene expression profile of B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> lungs may merely reflect increased inflammation in these lungs. Alternatively, the increased bacterial burdens may be due to a similarly enhanced type I IFN response in these mice, which leads to secondary bacterial outgrowth and inflammation. Therefore, we specifically compared the change in expression of two subsets of genes: (1) hallmark inflammatory response pathway (<xref ref-type="fig" rid="fig4">Figure 4C</xref>) and (2) type I interferon response genes (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). This analysis revealed that B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice not only show a similarly increased inflammatory gene signature, as expected, but in addition showed a similarly increased type I IFN gene signature. We validated the elevated expression of the ISG <italic>Il1rn</italic> in both B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice during <italic>M. tuberculosis</italic> infection by real-time quantitative¬†polymerase chain reaction¬†(RT-qPCR) (<xref ref-type="fig" rid="fig4s1">Figure 4‚Äîfigure supplement 1</xref>). The expression of <italic>Sp110</italic> and the SP family member <italic>Sp100</italic> in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice during <italic>M. tuberculosis</italic> infection was unimpaired compared to B6, and the expression level of <italic>Sp100</italic> was unchanged between <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> mice (<xref ref-type="fig" rid="fig4s2">Figure 4‚Äîfigure supplement 2</xref>). We also did not observe major changes in expression (&gt;2-fold change) of <italic>Sp100</italic> or <italic>Sp140</italic> in <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice during <italic>M. tuberculosis</italic> infection (<xref ref-type="fig" rid="fig4s2">Figure 4‚Äîfigure supplement 2</xref>). Overall, the expression of additional SP family members in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice is intact, which suggests that the targeting of these genes had specific rather than unanticipated epistatic effects. Therefore, deficiency in <italic>Sp140</italic> is likely the primary driver of susceptibility in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice, while the resistance of <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mice likely derives from normal expression of <italic>Sp140</italic> rather than aberrant changes in the expression of other SP family members.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Global gene expression analysis of <italic>Sp110<sup>‚Äì/‚Äì</sup>, Sp140<sup>‚Äì/‚Äì</sup></italic>,¬†and B6.<italic>Sst1<sup>S</sup></italic> lungs after <italic>Mycobacterium¬†tuberculosis</italic> infection.</title><p>(<bold>A</bold>) PCA or (<bold>B</bold>) Euclidean distance analysis of all the samples. (<bold>C,¬†D</bold>) Heatmaps of gene expression in log<sub>2</sub>-fold change from <italic>M. tuberculosis</italic>-infected B6. Genes shown are those significantly different between <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6. (<bold>C</bold>) GSEA Hallmark inflammatory response; and (<bold>D</bold>) GO type I IFN response genes. (<bold>E</bold>) Volcano plot comparing <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> to B6.<italic>Sst1<sup>S</sup></italic> expression. Dots in red are twofold differentially expressed with adjusted p-value¬†‚â§0.05.¬†PCA,¬†principal component analysis.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4‚Äîfigure supplement 1.</label><caption><title>B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> lungs exhibit elevated transcript levels of the interferon-stimulated gene <italic>Il1rn</italic> during <italic>Mycobacterium¬†tuberculosis</italic> infection.</title><p>RT-qPCR for <italic>Il1rn</italic> (encodes IL-1Ra) extracted from lungs at 28 days post-infection with <italic>M. tuberculosis.</italic> Combined results of two independent experiments. Mann-Whitney test. *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005.¬†RT-qPCR, real-time quantitative¬†polymerase chain reaction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4‚Äîfigure supplement 2.</label><caption><title>Expression of SP family members in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> mouse lungs during <italic>Mycobacterium¬†tuberculosis</italic> infection.</title><p>Log<sub>2</sub>-fold change and adjusted p-value for SP family members (<italic>Sp100, Sp110,</italic> and¬†<italic>Sp140</italic>) from RNA-seq of <italic>M. tuberculosis</italic>-infected lungs from <italic>Sp110<sup>‚Äì/‚Äì</sup></italic> and <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice, compared to B6 and B6.<italic>Sst1<sup>S</sup></italic>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Only 269 genes were significantly differentially expressed (adjusted p-value¬†&lt;0.05) between <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> samples, whereas 1520 genes were significantly differentially expressed between <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6. Within the 269 genes differentially expressed between <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic>, 62 were immunoglobulin genes, 62 were annotated as pseudogenes, and most differences are only of modest significance (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The differentially expressed genes are not linked to the <italic>Sst1<sup>S</sup></italic> locus, but could derive from the partial low expression of <italic>Sp140</italic> and the loss of <italic>Sp110</italic> in B6.<italic>Sst1<sup>S</sup></italic>, as compared to the complete loss of functional SP140 protein and retention of SP110 in <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice. Alternatively, the minor differences in gene expression between B6.<italic>Sst1<sup>S</sup></italic> and B6.<italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice could arise from additional genetic background or microbiota differences between B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice. Interestingly, the gene most significantly differentially expressed between B6.<italic>Sst1<sup>S</sup></italic> and <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice (i.e., with the smallest adjusted p<italic>-</italic>value) was <italic>Sp110</italic> (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). This result is expected, given that <italic>Sp110</italic> is not expressed in B6.<italic>Sst1<sup>S</sup></italic> but is retained in our <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice (<xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1D</xref>). Together, these results show that while they are not identical, the transcriptomes of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> mice greatly overlap during <italic>M. tuberculosis</italic> infection, and importantly, both strains exhibit a similar type I IFN signature. Given the susceptibility of B6.<italic>Sst1<sup>S</sup></italic> mice is due to overproduction of type I IFN (<xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>), we hypothesized that type I IFNs might also mediate the susceptibility of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice.</p></sec><sec id="s2-5"><title>Susceptibility of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice to bacterial infections depends on type I IFN signaling</title><p>To determine whether type I IFNs exacerbate <italic>M. tuberculosis</italic> infection of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice, <italic>M. tuberculosis</italic>-infected <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice were treated with a blocking antibody against IFNAR1. Compared to mice that only received isotype control antibody, <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice that received the anti-IFNAR1 antibody had reduced bacterial burdens in their lungs (<xref ref-type="fig" rid="fig5s1">Figure 5‚Äîfigure supplement 1</xref>). We also generated <italic>Sp140<sup>‚Äì/‚Äì¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> double-deficient mice and infected them with <italic>M. tuberculosis</italic> (<xref ref-type="fig" rid="fig5">Figure 5A-B</xref>). Loss of <italic>Ifnar</italic> protected <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice from weight loss (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and reduced bacterial burdens at day 25 post-infection, similar to those seen in B6 mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Furthermore, <italic>Sp140<sup>‚Äì/‚Äì¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> mice were partially protected from <italic>L. pneumophila</italic> infection, to a similar degree as B6.<italic>Sst1<sup>S¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5C-D</xref>). These results show that similar to B6.<italic>Sst1<sup>S</sup></italic> mice, type I IFN signaling is responsible for the susceptibility of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice to <italic>M. tuberculosis</italic>, and partially responsible for the susceptibility of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice to <italic>L. pneumophila</italic>.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Susceptibility of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> to <italic>Mycobacterium</italic>¬†<italic>tuberculosis</italic> and <italic>Legionella¬†pneumophila</italic> is dependent on type I IFN signaling.</title><p>(<bold>A,¬†B</bold>) Mice were infected with <italic>M. tuberculosis</italic> and measured for (<bold>A</bold>) body weight, and (<bold>B</bold>) bacterial burdens at day 25. Statistics in (<bold>A</bold>) show comparison to B6; data are from 9 B6, 13 <italic>Sp140<sup>‚Äì/‚Äì</sup></italic>, and 13¬†<italic>Sp140<sup>‚Äì/‚Äì</sup> Ifnar<sup>‚Äì/‚Äì</sup></italic> mice. Combined results of two experiments. (<bold>C,¬†D</bold>) Bacteria burden in <italic>L. pneumophila</italic>-infected mice at 96 hr. Combined results of two experiments. All mice were bred in-house (<bold>A,¬†B, D</bold>); all but B6 were bred in-house (<bold>C</bold>). Mann-Whitney test (<bold>A‚ÄìD</bold>). *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5‚Äîfigure supplement 1.</label><caption><title>Antibody blockade of IFNAR1 reduces bacterial burden in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> mice during <italic>Mycobacterium¬†tuberculosis</italic> infection.</title><p>Mice were infected with <italic>M. tuberculosis</italic> and treated with either IFNAR1-blocking antibody or isotype control starting 7 days post-infection. At 25 days post-infection, lungs were harvested to enumerate CFU. Results of one experiment. All mice were bred in-house. Mann-Whitney test. *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005.¬†CFU, colony-forming unit.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67290-fig5-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Humans and other vertebrates encounter diverse classes of pathogens, including viruses, bacteria, fungi, and parasites. In response, vertebrate immune systems have evolved stereotypical responses appropriate for distinct pathogen types. For example, type I IFN-driven immunity is generally critical for defense against viruses (<xref ref-type="bibr" rid="bib49">Schneider et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Stetson and Medzhitov, 2006</xref>), whereas type II IFN (IFN-Œ≥)-driven immunity mediates resistance to intracellular pathogens (<xref ref-type="bibr" rid="bib10">Crisler and Lenz, 2018</xref>). Additionally, IL-1 is important for inducing neutrophil and other responses against extracellular pathogens (<xref ref-type="bibr" rid="bib30">Mantovani et al., 2019</xref>), and IL-4/‚Äì13 (type 2 immunity) orchestrates responses to helminths and other parasites (<xref ref-type="bibr" rid="bib28">Locksley, 1994</xref>). Thus, an important question is how the immune system generates responses that are appropriate for resistance to a specific pathogen while repressing inappropriate responses. The alternative strategy of making all types of responses to all pathogens appears not to be employed, possibly because it would be too energetically costly, or incur too much inflammatory damage to the host. Although there is still much to be learned, it appears that negative feedback is essential to enforce choices between possible types of immune responses. For example, IL-4 and IFN-Œ≥ have long been appreciated to act as reciprocal negative antagonists of each other (<xref ref-type="bibr" rid="bib28">Locksley, 1994</xref>). In addition, anti-viral type I IFNs negatively regulate IFN-Œ≥ and IL-1-driven anti-bacterial responses via diverse mechanisms (<xref ref-type="bibr" rid="bib12">Donovan et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Moreira-Teixeira et al., 2018</xref>). Although negative regulation of IFN-Œ≥/IL-1 by type I IFN is likely beneficial to limit immunopathology during viral infections, <italic>Sst1<sup>S</sup></italic> mice provide an example of how excessive or inappropriate negative regulation by type I IFN can also be detrimental during bacterial infections (<xref ref-type="bibr" rid="bib19">He et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>). In this study, we therefore sought to understand the molecular basis by which wild-type (<italic>Sst1<sup>R</sup></italic>) mice are able to restrain type I IFNs appropriately during bacterial infections.</p><p>Although the <italic>Sst1</italic> locus was first described in 2005 (<xref ref-type="bibr" rid="bib38">Pan et al., 2005</xref>), further genetic analysis of the locus has been hindered by its extreme repetitiveness and the concomitant difficulty in generating specific loss-of-function mutations in <italic>Sst1</italic>-linked genes. In particular, the loss of <italic>Sp110 (Ipr1)</italic> has long been proposed to explain the susceptibility of <italic>Sst1</italic> mice to bacterial infections. However, while we could confirm the loss of <italic>Sp110</italic> expression in <italic>Sst1<sup>S</sup></italic> mice, specific <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> mice were never generated and thus its essential role in host defense has been unclear. The advent of CRISPR/Cas9-based methods of genome engineering allowed us to generate <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> mice. Unexpectedly, we found that¬†<italic>Sp110</italic><sup>‚Äì/‚Äì</sup> mice were fully resistant to <italic>M. tuberculosis</italic> infection, and we thus conclude that lack of <italic>Sp110</italic> is not sufficient to explain the <italic>Sst1<sup>S</sup></italic> phenotype. An important caveat of genetic studies of the <italic>Sst1</italic> locus is that generating specific gene knockouts is still nearly impossible in this genetic region, even with CRISPR/Cas9. Indeed, the guide sequence used to target exon 3 of <italic>Sp110</italic> also targets an unknown number of pseudogene copies of <italic>Sp110</italic>-like genes located within the unassembled adjacent ‚Äòhomogenously staining region‚Äô of mouse chromosome 1. Thus, we expect that additional off-target mutations are likely present in our <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> mutant mice. However, given that the <italic>Sp110</italic> pseudogenes are not known to be expressed, we consider it unlikely that collateral mutations would affect our conclusions. Moreover, any off-target mutations should differ among the three founder mice we analyzed and are thus unlikely to explain the consistent resistant phenotype we observed in all three founders. Additionally, we did not observe major changes in gene expression for other SP family members (<italic>Sp100</italic> and¬†<italic>Sp140</italic>) in <italic>Sp110</italic><sup>‚Äì/‚Äì</sup> mice during <italic>M. tuberculosis</italic> infection (<xref ref-type="fig" rid="fig4s2">Figure 4‚Äîfigure supplement 2</xref>). Finally, since we were able to establish that all the founders at a minimum lack SP110 protein, additional mutations would not affect our conclusion that <italic>Sp110</italic> is not essential for resistance to <italic>M. tuberculosis</italic>.</p><p>Given that loss of <italic>Sp110</italic> was not sufficient to explain the susceptibility of <italic>Sst1<sup>S</sup></italic> mice to bacterial infections, we considered other explanations. We found that <italic>Sst1<sup>S</sup></italic> mice also lack expression of <italic>Sp140</italic>, an <italic>Sst1</italic>-linked homolog of <italic>Sp110</italic>. Our data suggest that deletion of <italic>Sp140</italic> is sufficient to recapitulate the full <italic>Sst1<sup>S</sup></italic> phenotype including broad susceptibility to multiple bacterial infections, including <italic>M. tuberculosis</italic> and <italic>L. pneumophila</italic>. From the¬†analysis of RNA-seq data generated from <italic>M tuberculosis-</italic>infected lungs, we found that the transcriptomes of <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S</sup></italic> greatly overlap and display an elevated ISG signature. The elevated production of <italic>Ifnb</italic> mRNA and <italic>Il1rn</italic> mRNA seen by RNAseq was validated by RT-qPCR. Enhanced <italic>Ifnb</italic> production and <italic>Ifnar</italic>-dependent cell death were also observed during in vitro experiments with BMMs. A causative role for type I IFNs in the phenotype of <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> and <italic>Sst1<sup>S</sup></italic> mice was seen in the reduced susceptibility of <italic>Sp140<sup>‚Äì/‚Äì¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> and B6.<italic>Sst1<sup>S¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> mice to bacterial infection. Overall, we therefore conclude that loss of <italic>Sp140</italic> likely explains the <italic>Sst1</italic>-linked hyper type I IFN-driven susceptibility to bacterial infections. It remains possible that the additional loss of <italic>Sp110</italic> in <italic>Sst1<sup>S</sup></italic> mice further exacerbates the <italic>Sst1<sup>S</sup></italic> susceptibility phenotype as compared to <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice. However, in our studies, we did not observe a consistent difference in susceptibility between <italic>Sst1<sup>S</sup></italic> (i.e., <italic>Sp110</italic><sup>‚Äì/‚Äì¬†</sup><italic>Sp140</italic><sup>‚Äì/‚Äì</sup>) mice as compared to our <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice.</p><p>Another important caveat to our study is that it remains possible that our <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice carry additional mutations that contribute to, or even fully explain, their observed phenotype. This concern is somewhat ameliorated by our analysis of two independent <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> founders, both of which exhibited susceptibility to <italic>M. tuberculosis</italic> (<xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1E</xref>). We confirmed there is normal SP110 protein levels in bone marrow macrophages from <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice (<xref ref-type="fig" rid="fig2s1">Figure 2‚Äîfigure supplement 1D</xref>), and normal levels of <italic>Sp110</italic> and <italic>Sp100</italic> mRNA in the lungs of <italic>M. tuberculosis</italic>-infected <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice (<xref ref-type="fig" rid="fig4s2">Figure 4‚Äîfigure supplement 2</xref>). Thus, collateral loss of SP100 or SP110 is unlikely to explain the phenotype of our <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice. To address the possibility of mutations in unannotated SP-like genes, we used deep amplicon sequencing of genomic DNA and cDNA from <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice. We confirmed that both founder lines harbored distinct off-target mutations. Most of the identified off-target mutations are in previously unidentified sequences that likely originate from <italic>Sp140</italic> paralogs within the unmapped HSR. Most HSR-linked paralogs are believed to be pseudogenes, and indeed, the off-target mutated genes appear to be expressed at a far lower level than <italic>Sp140</italic> in lungs during <italic>M. tuberculosis</italic> infection. In one of our <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> lines, we identified an off-target mutated <italic>Sp140</italic>-like paralog that was expressed at detectable levels in the lungs of <italic>M. tuberculosis</italic>-infected mice. This paralog was 100% identical to <italic>Sp140</italic> in the sequenced region and was only distinguished from <italic>Sp140</italic> itself because it lacked the deletion that was introduced into the edited <italic>Sp140</italic> gene. Importantly, this previously undescribed <italic>Sp140</italic>-like expressed sequence was not mutated in our second <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> line and is thus unlikely to explain resistance to <italic>M. tuberculosis</italic> infection. As an alternative approach to confirm the phenotype of <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice is due to loss of <italic>Sp140</italic>, we overexpressed <italic>Sp140</italic> in <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs. Crucially, we found <italic>Sp140</italic> complements aberrant elevated <italic>Ifnb</italic> transcription exhibited by <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> BMMs upon TNFŒ± stimulation. Finally, <italic>Sp110</italic> and <italic>Sp140</italic> are the only two <italic>Sst1</italic>-linked genes that we were able to find to be differentially expressed between B6 and B6.<italic>Sst1</italic><sup>S</sup> mice, and as discussed above, our genetic studies suggest little role for the loss of <italic>Sp110</italic>. Thus, while it is formally possible that an edited <italic>Sp140</italic> homolog that was not identified by our amplicon sequencing contributes to the susceptibility to bacterial infection and elevated type I IFN in <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice, the most parsimonious explanation of our data is that deficiency in <italic>Sp140</italic> accounts for the <italic>Sst1<sup>S</sup></italic> phenotype. We expect that future mechanistic studies will be critical to further confirm this conclusion.</p><p>Because <italic>Sp140</italic> is inducible by IFN-Œ≥, our results suggest the existence of a novel feedback loop by which IFN-Œ≥ acts to repress the transcription of type I IFNs via SP140. This feedback loop appears to be essential for host defense against diverse bacterial pathogens. A major question that remains is how SP140 acts to repress the type I IFN response. SP140 contains DNA/chromatin-binding domains, such as SAND, PHD, and BRDs, which suggest the hypothesis that SP140 functions as a direct transcriptional repressor of type I IFN genes. However, much more indirect mechanisms are also possible. Recent studies suggest that hyper type I IFN responses in TNF-stimulated B6.<italic>Sst1<bold><sup>S</sup></bold></italic> BMMs derive from aberrant oxidative stress that activates the kinase JNK and ultimately results in a non-resolving stress response that promotes necrosis (<xref ref-type="bibr" rid="bib3">Bhattacharya et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Brownhill et al., 2020</xref>). Interestingly, mouse SP140 localizes to nuclear structures called PML bodies. PML bodies are implicated in a variety of cell processes, such as apoptosis, cell cycle, DNA damage response, senescence, and cell-intrinsic anti-viral responses (<xref ref-type="bibr" rid="bib47">Scherer and Stamminger, 2016</xref>). Whether or not the repressive effects of SP140 on type I IFN expression occur via the activity of PML bodies is an important outstanding question. Another major question is whether or how the repression of type I IFNs by SP140 is specific for bacterial infections and, if not, whether the presence of SP140 impairs anti-viral immunity. Finally, polymorphisms in human SP140 are associated with chronic lymphocytic leukemia, Crohn‚Äôs disease, and multiple sclerosis (<xref ref-type="bibr" rid="bib15">Franke et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">International IBD Genetics Consortium (IIBDGC) et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Karaky et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Matesanz et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Slager et al., 2013</xref>). Studies using siRNA and shRNA-mediated knockdown have also implicated SP140 in the repression of lineage-inappropriate genes in macrophages (<xref ref-type="bibr" rid="bib35">Mehta et al., 2017</xref>). Our generation of <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice is therefore important to permit future studies into these alternative roles of SP140.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Gene (<italic>Mus musculus</italic>)</td><td><italic>Sp110</italic></td><td>GenBank</td><td>Gene ID: 109032</td><td/></tr><tr><td>Gene (<italic>Mus musculus</italic>)</td><td><italic>Sp140</italic></td><td>GenBank</td><td>Gene ID: 434484</td><td/></tr><tr><td>Strain, strain background (<italic>M. tuberculosis,</italic> Erdman)</td><td><italic>M. tuberculosis</italic></td><td>Sarah Stanley, University of California, Berkeley</td><td>Erdman</td><td/></tr><tr><td>Strain, strain background (<italic>Legionella pneumophila,</italic> JR32 ŒîflaA)</td><td><italic>L. pneumophila</italic></td><td>Dario Zamboni, University of S√£o Paulo, Brazil</td><td>JR32</td><td/></tr><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td><italic>Sp110</italic><sup>‚Äì/‚Äì</sup></td><td>This paper</td><td/><td>(C57BL/6J background)</td></tr><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td><italic>Sp140</italic><sup>‚Äì/‚Äì</sup></td><td>This paper</td><td/><td>(C57BL/6J background)</td></tr><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td>B6.129S2-<italic>Ifnar1<sup>tm1Agt</sup></italic>/Mmjax</td><td>Jackson Laboratory</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MMRRC_032045-JAX">MMRRC_032045-JAX</ext-link></td><td/></tr><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td>B6J.C3-<italic>Sst</italic> <sup>C3HeB/FeJ</sup>Krmn</td><td>Igor Kramnik, Boston University</td><td/><td/></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>GP-2 293</td><td>UC Berkeley Cell culture Facility</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_WI48">CVCL_WI48</ext-link></td><td/></tr><tr><td>Antibody</td><td>Rabbit polyclonal anti-mouse SP110 (serum)</td><td>Covance, this paper</td><td/><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal anti-mouse SP140 (serum)</td><td>Covance, this paper</td><td/><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Mouse monoclonal anti-mouse SP110 (hybridoma)</td><td>Igor Kramnik, Boston University</td><td/><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Mouse anti-human IFNGR-Œ± chain (isotype control)</td><td>Leinco Technologies, Inc</td><td>Cat #: GIR208</td><td>Mouse injection (500 Œºg)</td></tr><tr><td>Antibody</td><td>Mouse anti-mouse IFNAR1</td><td>Leinco Technologies, Inc</td><td>Cat #: MAR1-5A3</td><td>Mouse injection (500 Œºg)</td></tr><tr><td>Recombinant DNA reagent</td><td>SINV-mincmvSp140-pgkAmetrine (plasmid)</td><td>This paper</td><td/><td>Derived from pTMGP vector (Addgene plasmid # 32716, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_32716">Addgene_32716</ext-link>)</td></tr><tr><td>Recombinant DNA reagent</td><td>SINV-Gal4-mincmv-mNeonGreen-pgkAmetrine (plasmid)</td><td>This paper</td><td/><td>Derived from pTMGP vector (Addgene plasmid # 32716, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_32716">Addgene_32716</ext-link>)</td></tr><tr><td>Recombinant DNA reagent</td><td>pMD2.G</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_12259">Addgene_12259</ext-link> <break/>plasmid #32716</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>Recombinant murine TNF¬†alpha</td><td>R&amp;D Systems</td><td>Cat #: 410-TRNC-010</td><td>BMM stimulation (10 ng/mL)</td></tr><tr><td>Peptide, recombinant protein</td><td>Recombinant murine interferon gamma</td><td>Biolegend</td><td>Cat #: 575304</td><td>BMM stimulation (5‚Äì10 ng/mL)</td></tr><tr><td>Peptide, recombinant protein</td><td>Retronectin</td><td>Takara</td><td>T100</td><td/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Sp110 fwd</td><td valign="top">This paper</td><td valign="top">Genotyping primers (<italic>Sp110)</italic></td><td valign="top">CTCTCCGCTCGGTGACTAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Sp110 rev</td><td valign="top">This paper</td><td valign="top">Genotyping primers (<italic>Sp110)</italic></td><td valign="top">CTGCACATGTGACAAGGATCTC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Sp140-1 fwd</td><td valign="top">This paper</td><td valign="top">Genotyping primers (<italic>Sp140)</italic></td><td valign="top">ACGAATAGCAAGCAGGAATGCT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Sp140-1 rev</td><td valign="top">This paper</td><td valign="top">Genotyping primers (<italic>Sp140)</italic></td><td valign="top">GGTTCCGGCTGAGCACTTAT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Sp140-2 fwd</td><td valign="top">This paper</td><td valign="top">Genotyping primers (<italic>Sp140)</italic></td><td valign="top">TGAGGACAGAACTCAGGGAG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Sp140-2 rev</td><td valign="top">This paper</td><td valign="top">Genotyping primers (<italic>Sp140)</italic></td><td valign="top">ACACGCCTTTAATCCCAGCATTT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ifnb</italic> sense</td><td valign="top">This paper</td><td valign="top">RT-qPCR primers (<italic>Ifnb</italic>)</td><td valign="top">GTCCTCAACTGCTCTCCACT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ifnb</italic> antisense</td><td valign="top">This paper</td><td valign="top">RT-qPCR primers (<italic>Ifnb</italic>)</td><td valign="top">CCTGCAACCACCACTCATTC</td></tr><tr><td>Commercial assay or kit</td><td>E.Z.N.A. Total RNA Kit I</td><td>Omega Biotek</td><td>Cat #: R6834-02</td><td/></tr><tr><td>Chemical compound, drug</td><td>polyI:C</td><td>Invivogen</td><td>Cat #: tlrl-picw</td><td>BMM stimulation (100 Œºg/mL)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>All mice were specific pathogen-free, maintained under a 12 hr light-dark cycle (7¬†a.m. to 7¬†p.m.), and given a standard chow diet (Harlan irradiated laboratory animal diet) ad libitum. All mice were sex- and age-matched at 6‚Äì10 weeks old at the beginning of infections. Littermates were used as indicated in the figure legends. C57BL/6J (B6) and B6.129S2-<italic>Ifnar1<sup>tm1Agt</sup></italic>/Mmjax (<italic>Ifnar<sup>‚Äì/‚Äì</sup>)</italic> were originally purchased from Jackson Laboratories and subsequently bred at UC Berkeley. B6J.C3-<italic>Sst</italic><sup>C3HeB/FeJ</sup>Krmn mice (referred to as B6.<italic>Sst1</italic><sup>S</sup> throughout) were from the colony of I. Kramnik at Boston University and then transferred to UC Berkeley. CRISPR/Cas9 targeting was performed by pronuclear injection of Cas9 mRNA and sgRNA into fertilized zygotes from colony-born C57BL/6J mice, essentially as described previously (<xref ref-type="bibr" rid="bib55">Wang et al., 2013</xref>). Founder mice were genotyped as described below, and founders carrying <italic>Sp140</italic> mutations were bred one generation to C57BL/6J to separate modified <italic>Sp140</italic> haplotypes. Homozygous lines were generated by interbreeding heterozygotes carrying matched <italic>Sp140</italic> haplotypes. <italic>Sp140<sup>‚Äì/‚Äì¬†</sup>Ifnar<sup>‚Äì/‚Äì</sup></italic> mice¬†were generated by crossing the <italic>Sp140<sup>‚Äì/‚Äì</sup></italic> and <italic>Ifnar<sup>‚Äì/‚Äì</sup></italic> mice in-house. All animals used in experiments were bred in-house unless otherwise noted in the figure legends. All animal experiments complied with the regulatory standards of, and were approved by, the University of California Berkeley Institutional Animal Care and Use Committee.</p></sec><sec id="s4-2"><title>Genotyping of <italic>Sp110</italic> alleles</title><p>Exon 3 and the surrounding intronic regions were amplified by PCR using the following primers (all 5‚Ä≤‚Äì3‚Ä≤): Sp110 fwd, <named-content content-type="sequence">CTCTCCGCTCGGTGACTAC</named-content>, and rev, <named-content content-type="sequence">CTGCACATGTGACAAGGATCTC</named-content>. The primer combinations were designed to distinguish <italic>Sp110</italic> from other <italic>Sp110</italic>-like genes. Primers were used at 200 nM in each 20 Œºl reaction with 1√ó Dreamtaq Green PCR Master Mix (Thermo Fisher Scientific). Cleaned PCR products were diluted at 1:10 and sequenced using Sanger sequencing (Elim Biopharm).</p></sec><sec id="s4-3"><title>Genotyping of <italic>Sp140</italic> alleles</title><p>Exon 3 and the surrounding intronic regions were amplified by bracket PCR using the following primers (all 5‚Ä≤‚Äì3‚Ä≤): Sp140-1 fwd, <named-content content-type="sequence">ACGAATAGCAAGCAGGAATGCT</named-content>, and rev, <named-content content-type="sequence">GGTTCCGGCTGAGCACTTAT</named-content>. The PCR products are diluted at 1:10 and 2 Œºl were used as template for the second PCR using the following primers: Sp140-2 fwd, <named-content content-type="sequence">TGAGGACAGAACTCAGGGAG</named-content>, and rev, <named-content content-type="sequence">ACACGCCTTTAATCCCAGCATTT</named-content>. The primer combinations were designed to distinguish <italic>Sp140</italic> from other <italic>Sp140</italic>-like genes. Primers were used at 200 nM in each 20 Œºl reaction with 1√ó Dreamtaq Green PCR Master Mix (Thermo Fisher Scientific). Cleaned PCR products were diluted at 1:10 and sequenced using Sanger sequencing (Elim Biopharm). PCRs were performed as described above for <italic>Sp110</italic> and sequenced using Sanger sequencing (Elim Biopharm).</p></sec><sec id="s4-4"><title><italic>Mycobacterium tuberculosis</italic> infections</title><p><italic>M. tuberculosis</italic> strain Erdman (gift of S.A. Stanley) was used for all infections. Frozen stocks of this wild-type strain were made from a single culture and used for all experiments. Cultures for infection were grown in Middlebrook 7H9 liquid medium supplemented with 10% albumin-dextrose-saline, 0.4% glycerol, and 0.05% Tween-80 for 5 days at 37¬∞C. Mice were aerosol infected using an inhalation exposure system (Glas-Col, Terre Haute, IN). A total of 9 ml of diluted culture was loaded into the nebulizer calibrated to deliver¬†~20‚Äì50 bacteria per mouse as confirmed by measurement of CFUs in the lungs 1 day following infection. Mice were sacrificed at various days post-infection (as described in figure legends) to measure CFUs and RNA levels. All but one lung lobe was homogenized in phosphate-buffered saline¬†(PBS) plus 0.05% Tween-80, and serial dilutions were plated on 7H11 plates supplemented with 10% oleic acid, albumin, dextrose, and¬†catalase and 0.5% glycerol. CFUs were counted 21 days after plating. The remaining lobe was used for histology or for RNA extraction. For histology, the sample was fixed in 10% formalin for at least 48 hr then stored in 70% ethanol. Samples were sent to Histowiz Inc for embedding in wax, sectioning and staining with H&amp;E. For histologic grading, slides were scanned at 20√ó magnification and evaluated by a trained pathologist (Stephen L. Nishimura) for the extent of macrophage, lymphoid, and granulocytic infiltration. The extent of infiltration was graded on a 0‚Äì4 scale with 0 being the least and four being the greatest. The extent of necrosis was similarly estimated. For survival experiments, mice were monitored for weight loss and were euthanized when they reached a humane endpoint as determined by the University of California Berkeley Institutional Animal Care and Use Committee.</p></sec><sec id="s4-5"><title><italic>Legionella pneumophila</italic> infections</title><p>Infections were performed using <italic>L. pneumophila</italic> strain JR32 Œî<italic>flaA</italic> (from the lab of D.S. Zamboni) as previously described (<xref ref-type="bibr" rid="bib17">Gon√ßalves et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Mascarenhas et al., 2015</xref>). Briefly, frozen cultures were streaked out on to BCYE plates to obtain single colonies. A single colony was chosen and streaked on to a new BCYE plate to obtain a 1 cm by 1 cm square bacterial lawn, and incubated for 2 days at 37¬∞C. The patch was solubilized in autoclaved MilliQ water and the optical density was measured at 600 nm. Culture was diluted to 2.5 √ó 10<sup>6</sup> bacteria/ml in sterile PBS. The mice were first anesthetized with ketamine and xylazine (90 mg/kg and 5 mg/kg, respectively) by intraperitoneal injection then infected intranasally with 40 ŒºL with PBS containing a final dilution of 1¬†√ó¬†10<sup>5</sup> bacteria per mouse. For enumerating CFUs, the lungs were harvested and homogenized in 5 mL of autoclaved MilliQ water for 30 s, using a tissue homogenizer. Lung homogenates were diluted in autoclaved MilliQ water and plated on BCYE agar plates. CFUs¬†were enumerated after plates were incubated for 4 days at 37¬∞C.</p></sec><sec id="s4-6"><title>Bone marrow-derived macrophages and TNF¬†treatment</title><p>Bone marrow was harvested from mouse femurs and tibias, and cells were differentiated by culture on non-tissue culture-treated plates in RPMI supplemented with supernatant from 3T3-MCSF cells (gift of B. Beutler), 10% fetal bovine serum (FBS) (Gibco, CAT#16140071, LOT#1447825), 2 mM glutamine, 100 U/ml streptomycin, and 100 Œºg/ml penicillin in a humidified incubator (37¬∞C, 5% CO<sub>2</sub>). BMMs were harvested 6 days after plating and frozen in 95% FBS and 5% DMSO. For in vitro experiments, BMMs were thawed into media as described above for 4 hr in a humidified 37¬∞C incubator. Adherent cells were washed with PBS, counted and replated at 1.2 √ó 10<sup>6</sup>‚Äì1.5 √ó 10<sup>6</sup> cells/well in a TC-treated six-well plate. Cells were treated with 10 ng/ml recombinant mouse TNFŒ± (410-TRNC-010, R&amp;D Systems) diluted in the media as described above.</p></sec><sec id="s4-7"><title>Quantitative/conventional RT-PCR</title><p>Total RNA from BMMs was extracted using E.Z.N.A. Total RNA Kit I (Omega Bio-tek) according to manufacturer's specifications. Total RNA from infected tissues was extracted by homogenizing in TRIzol reagent (Life Technologies) then mixing thoroughly with chloroform, both done under BSL3 conditions. Samples were then removed from the BSL3 facility and transferred to fresh tubes under BSL2 conditions. Aqueous phase was separated by centrifugation and RNA was further purified using the E.Z.N.A. Total RNA Kit I (Omega Bio-tek). Equal amounts of RNA from each sample were treated with DNase (RQ1, Promega) and cDNA was made using Superscript III (Invitrogen). Complementary cDNA reactions were primed with poly(dT) for the measurement of mature transcripts. For experiments with multiple time points, macrophage samples were frozen in the RLT buffer (Qiagen) and infected tissue samples in RNA<italic>later</italic> solution (Invitrogen) and processed to RNA at the same time. Quantitative PCR was performed using QuantiStudio 5 Real-Time PCR System (Applied Biosystems) with Power Sybr Green PCR Master Mix (Thermo Fisher Scientific) according to manufacturer's specifications. Transcript levels were normalized to housekeeping genes <italic>Rps17, Actb,</italic> and <italic>Oaz1</italic> unless otherwise specified. The following primers were used in this study. <italic>Rps17</italic> sense: <named-content content-type="sequence">CGCCATTATCCCCAGCAAG;</named-content> <italic>Rps17</italic> antisense: <named-content content-type="sequence">TGTCGGGATCCACCTCAATG</named-content>; <italic>Oaz1</italic> sense: <named-content content-type="sequence">GTGGTGGCCTCTACATCGAG</named-content>; <italic>Oaz1</italic> antisense: <named-content content-type="sequence">AGCAGATGAAAA CGTGGTCAG</named-content>; <italic>Actb</italic> sense: <named-content content-type="sequence">CGCAGCCACTGTCGAGTC</named-content>; <italic>Actb</italic> antisense: <named-content content-type="sequence">CCTTCTGACCCATTCCCACC</named-content>; <italic>Ifnb</italic> sense: <named-content content-type="sequence">GTCCTCAACTGCTCTCCACT</named-content>; <italic>Ifnb</italic> antisense: <named-content content-type="sequence">CCTGCAACCACCACTCATTC</named-content>; <italic>Gbp4</italic> sense: <named-content content-type="sequence">TGAGTACCTGGAGAATGCCCT</named-content>; <italic>Gbp4</italic> antisense: <named-content content-type="sequence">TGGCCGAATTGGATGCTTGG</named-content>; <italic>Ifit3</italic> sense: <named-content content-type="sequence">AGCCCACACCCAGCTTTT</named-content>; <italic>Ifit3</italic> antisense: <named-content content-type="sequence">CAGAGATTCCCGGTTGACCT</named-content>; <italic>Tnfa</italic> sense: <named-content content-type="sequence">TCTTCTCATTCCTGCTTGTGG</named-content>; and¬†<italic>Tnfa</italic> antisense: <named-content content-type="sequence">GGTCTGGGCCATAGAACTGA</named-content>. Conventional RT-PCR shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref> used the following primers. Sense: <named-content content-type="sequence">GTCCCTTGGAGTCTGTGTAGG</named-content>; antisense: <named-content content-type="sequence">CATCCTGGGGCTCTTGTCTTG</named-content>.</p></sec><sec id="s4-8"><title>Immunoblot</title><p>Samples were lysed in RIPA buffer with protease inhibitor cocktail (Roche) to obtain total protein lysate and were clarified by spinning at¬†~16,000√ó<italic>g</italic> for 30 min at 4¬∞C. Clarified lysates were analyzed with Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) according to the¬†manufacturer's specification and diluted to the same concentration and denatured with SDS-loading buffer. Samples were separated on NuPAGE Bis‚ÄìTris 4‚Äì12% gradient gels (Thermo Fisher Scientific) following the manufacturer‚Äôs protocol. Gels were transferred onto ImmobilonFL PVDF membranes at 35 V for 90 min and blocked with Odyssey blocking buffer (Li-Cor). Proteins were detected on a Li-Cor Odyssey Blot Imager using the following primary and secondary antibodies. Rabbit anti-SP110 or SP140 serums were produced by Covance and used at 1:1000 dilution. Hybridoma cells expressing monoclonal anti-SP110 antibody were from the lab of I. Kramnik. Antibodies were produced in-house as previously described (<xref ref-type="bibr" rid="bib22">Ji et al., 2019</xref>) and used at 100 ng/mL. Alexa Fluor 680-conjugated secondary antibodies (Invitrogen) were used at 0.4 mg/mL.</p></sec><sec id="s4-9"><title>RNA sequencing and analysis</title><p>Total RNA was isolated as described above. Illumina-compatible libraries were generated by the University of California, Berkeley, QB3 Vincent J. Coates Genomics Sequencing Laboratory. PolyA selection was performed to deplete rRNA. Libraries were constructed using Kapa Biosystem library preparation kits. The libraries were multiplexed and sequenced using one flow cell on Novaseq 6000 (Illumina) as 50 bp paired-end reads. Base calling was performed using bcl2fastq2 v2.20. The sequences were aligned to mm10 genome using Kallisto v.0.46.0 using standard parameters (<xref ref-type="bibr" rid="bib42">Pimentel et al., 2017</xref>) and analyzed using Deseq2 (<xref ref-type="bibr" rid="bib29">Love et al., 2014</xref>) and DEVis packages (<xref ref-type="bibr" rid="bib44">Price et al., 2019</xref>). For Deseq2 and DEVis analysis, all raw counts were incremented by one to avoid excluding genes due to division by 0 in the normalization process, except for data shown in <xref ref-type="fig" rid="fig4s2">Figure 4‚Äîfigure supplement 2</xref>. Fold changes were calculated with the apeglm shrinkage estimator (<xref ref-type="bibr" rid="bib58">Zhu et al., 2019</xref>).</p></sec><sec id="s4-10"><title>Antibody-mediated neutralization</title><p>Mice were given anti-IFNAR1 antibody or isotype control once every 2 days, starting 7 days post-infection. All treatments were delivered by intraperitoneal injection. Mouse anti-mouse IFNAR1 (MAR1-5A3) and isotype control (GIR208, mouse anti-human IFNGR-Œ± chain) were purchased from Leinco Technologies Inc. For injections, antibody stocks were diluted in sterile PBS and each mouse received 500 Œºg per injection.</p></sec><sec id="s4-11"><title>Amplicon sequencing and analysis</title><p>Amplicons comprising the 5‚Ä≤¬†intron of exon 3 of <italic>Sp140</italic> and the end of exon 3 were amplified from crude DNA from ear clips of B6 and <italic>Sp140</italic><sup>‚Äì/‚Äì</sup>founder¬†line¬†1 mice (sense: <named-content content-type="sequence">TCATATAACCCATAAATCCATCATGACA</named-content>; antisense: <named-content content-type="sequence">CCATTTAGGAAGAAGTGTTTTAGAGTCT</named-content>) with PrimeStar PCR components (Takara, R010b) for 18 cycles according to manufacturer's specifications, then diluted 50-fold and barcoded for an additional 18 cycles with Illumina-compatible sequencing adaptors. Amplicons of <italic>Sp140</italic> exon 3 (sense: <named-content content-type="sequence">AATATCAAGAAACATGTAAGAACCTGGT</named-content>; antisense: <named-content content-type="sequence">CCATTTAGGAAGAAGTGTTTTAGAGTCT</named-content>) and exons 2‚Äì3 (sense: <named-content content-type="sequence">GCAGAAGTTTCAGGAATATCAAGAAACATGTAAG</named-content>; antisense: <named-content content-type="sequence">ACTTCTTCTGTACATTGCTGAGGATGT</named-content>) were amplified from cDNA generated from lungs of B6,¬†andboth lines of <italic>Sp140</italic><sup>‚Äì/‚Äì</sup> mice infected with <italic>M. tuberculosis</italic> for 25 cycles with PrimeStar before barcoding. Libraries were generated by the University of California, Berkeley, QB3 Vincent J. Coates Genomics Sequencing Laboratory, and were multiplexed and sequenced on an Illumina Miseq platform with v2 chemistry and 300 bp single-end reads for DNA amplicons, and Illumina Miseq Nano platform with v3 chemistry for 300 bp single-end reads for cDNA amplicons. Reads were aligned with Burrows-Wheeler Aligner (BWA-MEM) with default parameters (<xref ref-type="bibr" rid="bib26">Li, 2013</xref>; <xref ref-type="bibr" rid="bib27">Li and Durbin, 2009</xref>) to chromosome one and non-localized genome contigs of the <italic>Mus musculus</italic> genome (assembly mm10) as well as the <italic>Sp140</italic> gene and transcript X1¬†(XM_030255396.1), converted to BAM files with samtools (<xref ref-type="bibr" rid="bib25">Li et al., 2009</xref>), and visualized in IGV 2.8. Subsets of reads were extracted from alignment files using the Seqkit toolkit (<xref ref-type="bibr" rid="bib50">Shen et al., 2016</xref>).</p></sec><sec id="s4-12"><title>Retroviral transduction of BMMs</title><p>Self-inactivating pTMGP vector (SINV) with either a minimal CMV promoter driving <italic>Sp140</italic> or a minimal CMV promoter and 4 Gal4 binding sites driving mNeonGreen, and the reporter mAmetrine driven by a PGK promoter, were cloned using Infusion (638910, Takara). pTGMP was from the lab of Scott Lowe (Addgene plasmid # 32716). Virus was harvested from GP-2 cells transfected with SINV vectors and VSV-G (pMD2.G, Addgene plasmid #12259) and grown in DMEM supplemented with 30% FBS and 2 mM glutamine, 100 U/ml streptomycin, and 100 Œºg/ml penicillin (adapted from protocols described in <xref ref-type="bibr" rid="bib48">Schmidt et al., 2015</xref>). Harvested virus was concentrated 100-fold by ultracentrifugation in RPMI before storage at ‚àí80¬∞C. Virus was thawed and titrated on bone marrow to optimize transduction efficiency. Bone marrow was harvested as described above and the entirety of the bone marrow was plated in a non-TC 15 cm plate. The next day, bone marrow was harvested and transduced with SINV virus on plates coated with 10 Œºg/cm<sup>2</sup> Retronectin (T100, Takara) for 1.5‚Äì2 hr at 650√ó<italic>g</italic> and 37¬∞C. After 2 days of additional culture, media was replenished, then transduced bone marrow was cultured for 3 additional days before sorting. Sorted transduced macrophages were stimulated with 5 ng/mL recombinant murine IFN-Œ≥ (575304, Biolegend) 12‚Äì14 hr before stimulation with 10 ng/mL recombinant TNFŒ± as described above for 4 hr (FBS used in these experiments was from Omega, LOT 721017, CAT# FB-12). RNA isolation and RT-qPCR were performed as described above. No mycoplasma contamination was detected by PCR in GP-2 cells used for these experiments (sense: <named-content content-type="sequence">CACCATCTGTCACTCTGTTAACC</named-content>; antisense: <named-content content-type="sequence">GGAGCAAACAGGATTAGATACCC</named-content>), and GP-2 cells were authenticated by short tandem repeat DNA profiling by the UC Berkeley DNA Sequencing Facility.</p></sec><sec id="s4-13"><title>Quantification of cell death upon polyI:C treatment</title><p>Primary BMMs were derived from fresh or frozen bone marrow as described above¬†for¬†6-7¬†days. BMMs were plated at 50,000‚Äì90,000 cells per well in 96-well non-TC treated plates, and stimulated for 16‚Äì24 hr with 100 Œºg/mL polyI:C (tlrl-picw, Invivogen). LDH assays were performed on supernatants after stimulation as previously described (<xref ref-type="bibr" rid="bib11">Decker and Lohmann-Matthes, 1988</xref>). Similar results were obtained for BMMs cultured with FBS from Omega and Gibco (LOT 721017, CAT# FB-12, and LOT# 1447825, CAT#16140071, respectively).</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>All data were analyzed with Mann-Whitney test unless otherwise noted. Tests were run using GraphPad Prism 5. *p‚â§0.05; **p‚â§0.01; ***p‚â§0.005. All error bars are S.E. Figures show exact p-values for p&gt;0.0005.</p></sec><sec id="s4-15"><title>Data accession</title><p>RNA-seq data is available at GEO, accession number GSE166114. Amplicon sequencing data is available at the SRA, BioProject accession number PRJNA698382.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The¬†authors thank the Stanley and Cox laboratories for support with <italic>M. tuberculosis</italic> experiments, L Flores, P¬†Dietzen, and R Chavez for technical assistance, and members of the Vance, Barton, Cox, Stanley, and Portnoy labs for advice and discussions. Funding: REV is supported by an Investigator Award from the Howard Hughes Medical Institute. This work was also supported by NIH grants R37AI075039 and R01AI155634 (REV), P01AI066302 (REV and DAP), and R01HL134183 (SLN). REV and KHD were Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf2"><p>consults for Ventus Therapeutics and is a Reviewing Editor for <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con12"><p>Supervision, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal studies were approved by the UC Berkeley Animal Care and Use Committee (current protocol number: AUP-2014-09-6665-2).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-67290-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>RNA-seq data is available at GEO, accession number GSE166114. Amplicon sequencing data is available at the SRA, BioProject accession number PRJNA698382.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Role of the transcriptional regulator SP140 in resistance to bacterial infection via repression of type I interferons</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166114">GSE166114</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Witt</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Deep amplicon sequencing of Sp140-like genes in Mus musculus</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA698382">PRJNA698382</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>MS</given-names></name><name><surname>Su</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>AIRE expands: new roles in immune tolerance and beyond</article-title><source>Nature Reviews Immunology</source><volume>16</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.9</pub-id><pub-id pub-id-type="pmid">26972725</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auerbuch</surname> <given-names>V</given-names></name><name><surname>Brockstedt</surname> <given-names>DG</given-names></name><name><surname>Meyer-Morse</surname> <given-names>N</given-names></name><name><surname>O'Riordan</surname> <given-names>M</given-names></name><name><surname>Portnoy</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes</article-title><source>Journal of Experimental Medicine</source><volume>200</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1084/jem.20040976</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname> <given-names>B</given-names></name><name><surname>Xiao</surname> <given-names>S</given-names></name><name><surname>Chatterjee</surname> <given-names>S</given-names></name><name><surname>Urbanowski</surname> <given-names>M</given-names></name><name><surname>Ordonez</surname> <given-names>A</given-names></name><name><surname>Ihms</surname> <given-names>EA</given-names></name><name><surname>Agrahari</surname> <given-names>G</given-names></name><name><surname>Lun</surname> <given-names>S</given-names></name><name><surname>Berland</surname> <given-names>R</given-names></name><name><surname>Pichugin</surname> <given-names>A</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Connor</surname> <given-names>J</given-names></name><name><surname>Ivanov</surname> <given-names>AR</given-names></name><name><surname>Yan</surname> <given-names>B-S</given-names></name><name><surname>Kobzik</surname> <given-names>L</given-names></name><name><surname>Koo</surname> <given-names>B-B</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name><name><surname>Bishai</surname> <given-names>W</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The integrated stress response mediates necrosis in murine Mycobacterium tuberculosis granulomas</article-title><source>Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e130319</elocation-id><pub-id pub-id-type="doi">10.1172/JCI130319</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottomley</surname> <given-names>MJ</given-names></name><name><surname>Collard</surname> <given-names>MW</given-names></name><name><surname>Huggenvik</surname> <given-names>JI</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Gibson</surname> <given-names>TJ</given-names></name><name><surname>Sattler</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation</article-title><source>Nature Structural Biology</source><volume>8</volume><fpage>626</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1038/89675</pub-id><pub-id pub-id-type="pmid">11427895</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boxx</surname> <given-names>GM</given-names></name><name><surname>Cheng</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The roles of type I interferon in bacterial infection</article-title><source>Cell Host &amp; Microbe</source><volume>19</volume><fpage>760</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.05.016</pub-id><pub-id pub-id-type="pmid">27281568</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyartchuk</surname> <given-names>V</given-names></name><name><surname>Rojas</surname> <given-names>M</given-names></name><name><surname>Yan</surname> <given-names>BS</given-names></name><name><surname>Jobe</surname> <given-names>O</given-names></name><name><surname>Hurt</surname> <given-names>N</given-names></name><name><surname>Dorfman</surname> <given-names>DM</given-names></name><name><surname>Higgins</surname> <given-names>DE</given-names></name><name><surname>Dietrich</surname> <given-names>WF</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The host resistance locus <italic>sst1</italic> controls innate immunity to <italic>Listeria monocytogenes</italic> infection in immunodeficient mice</article-title><source>Journal of Immunology</source><volume>173</volume><fpage>5112</fpage><lpage>5120</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.8.5112</pub-id><pub-id pub-id-type="pmid">15470055</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Brownhill</surname> <given-names>E</given-names></name><name><surname>Yabaji</surname> <given-names>SM</given-names></name><name><surname>Zhernovkov</surname> <given-names>V</given-names></name><name><surname>Rukhlenko</surname> <given-names>OS</given-names></name><name><surname>Seidel</surname> <given-names>K</given-names></name><name><surname>Bhattacharya</surname> <given-names>B</given-names></name><name><surname>Chatterjee</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>HA</given-names></name><name><surname>Crossland</surname> <given-names>N</given-names></name><name><surname>Bishai</surname> <given-names>W</given-names></name><name><surname>Kholodenko</surname> <given-names>BN</given-names></name><name><surname>Gimelbrant</surname> <given-names>A</given-names></name><name><surname>Kobzik</surname> <given-names>L</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Maladaptive oxidative stress cascade drives type I interferon hyperactivity in TNF activated macrophages promoting necrosis in murine tuberculosis granulomas</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.14.422743</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrero</surname> <given-names>JA</given-names></name><name><surname>Calderon</surname> <given-names>B</given-names></name><name><surname>Unanue</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection</article-title><source>Journal of Experimental Medicine</source><volume>200</volume><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1084/jem.20040769</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>S-Y</given-names></name><name><surname>Chen</surname> <given-names>M-L</given-names></name><name><surname>Lee</surname> <given-names>M-R</given-names></name><name><surname>Liang</surname> <given-names>Y-C</given-names></name><name><surname>Lu</surname> <given-names>T-P</given-names></name><name><surname>Wang</surname> <given-names>J-Y</given-names></name><name><surname>Yan</surname> <given-names>B-S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>SP110</italic> Polymorphisms Are Genetic Markers for Vulnerability to Latent and Active Tuberculosis Infection in Taiwan</article-title><source>Disease Markers</source><volume>2018</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2018/4687380</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crisler</surname> <given-names>WJ</given-names></name><name><surname>Lenz</surname> <given-names>LL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Crosstalk between type I and II interferons in regulation of myeloid cell responses during bacterial infection</article-title><source>Current Opinion in Immunology</source><volume>54</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2018.05.014</pub-id><pub-id pub-id-type="pmid">29886270</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname> <given-names>T</given-names></name><name><surname>Lohmann-Matthes</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity</article-title><source>Journal of Immunological Methods</source><volume>115</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(88)90310-9</pub-id><pub-id pub-id-type="pmid">3192948</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname> <given-names>ML</given-names></name><name><surname>Schultz</surname> <given-names>TE</given-names></name><name><surname>Duke</surname> <given-names>TJ</given-names></name><name><surname>Blumenthal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Type I interferons in the pathogenesis of tuberculosis: molecular drivers and immunological consequences</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>1633</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01633</pub-id><pub-id pub-id-type="pmid">29230217</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorhoi</surname> <given-names>A</given-names></name><name><surname>Yeremeev</surname> <given-names>V</given-names></name><name><surname>Nouailles</surname> <given-names>G</given-names></name><name><surname>Weiner</surname> <given-names>J</given-names></name><name><surname>J√∂rg</surname> <given-names>S</given-names></name><name><surname>Heinemann</surname> <given-names>E</given-names></name><name><surname>Oberbeck-M√ºller</surname> <given-names>D</given-names></name><name><surname>Knaul</surname> <given-names>JK</given-names></name><name><surname>Vogelzang</surname> <given-names>A</given-names></name><name><surname>Reece</surname> <given-names>ST</given-names></name><name><surname>Hahnke</surname> <given-names>K</given-names></name><name><surname>Mollenkopf</surname> <given-names>HJ</given-names></name><name><surname>Brinkmann</surname> <given-names>V</given-names></name><name><surname>Kaufmann</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics</article-title><source>European Journal of Immunology</source><volume>44</volume><fpage>2380</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1002/eji.201344219</pub-id><pub-id pub-id-type="pmid">24782112</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname> <given-names>GJ</given-names></name><name><surname>Sy</surname> <given-names>DN</given-names></name><name><surname>Nhung</surname> <given-names>NV</given-names></name><name><surname>Yu</surname> <given-names>B</given-names></name><name><surname>Ellis</surname> <given-names>MK</given-names></name><name><surname>Van Hung</surname> <given-names>N</given-names></name><name><surname>Cuong</surname> <given-names>NK</given-names></name><name><surname>Thi Lien</surname> <given-names>L</given-names></name><name><surname>Marks</surname> <given-names>GB</given-names></name><name><surname>Saunders</surname> <given-names>BM</given-names></name><name><surname>Britton</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Polymorphisms of SP110 are associated with both pulmonary and extra-pulmonary tuberculosis among the vietnamese</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e99496</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0099496</pub-id><pub-id pub-id-type="pmid">25006821</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname> <given-names>A</given-names></name><name><surname>McGovern</surname> <given-names>DP</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Radford-Smith</surname> <given-names>GL</given-names></name><name><surname>Ahmad</surname> <given-names>T</given-names></name><name><surname>Lees</surname> <given-names>CW</given-names></name><name><surname>Balschun</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Roberts</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>CA</given-names></name><name><surname>Bis</surname> <given-names>JC</given-names></name><name><surname>Bumpstead</surname> <given-names>S</given-names></name><name><surname>Ellinghaus</surname> <given-names>D</given-names></name><name><surname>Festen</surname> <given-names>EM</given-names></name><name><surname>Georges</surname> <given-names>M</given-names></name><name><surname>Green</surname> <given-names>T</given-names></name><name><surname>Haritunians</surname> <given-names>T</given-names></name><name><surname>Jostins</surname> <given-names>L</given-names></name><name><surname>Latiano</surname> <given-names>A</given-names></name><name><surname>Mathew</surname> <given-names>CG</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Prescott</surname> <given-names>NJ</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Schumm</surname> <given-names>P</given-names></name><name><surname>Sharma</surname> <given-names>Y</given-names></name><name><surname>Simms</surname> <given-names>LA</given-names></name><name><surname>Taylor</surname> <given-names>KD</given-names></name><name><surname>Whiteman</surname> <given-names>D</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Baldassano</surname> <given-names>RN</given-names></name><name><surname>Barclay</surname> <given-names>M</given-names></name><name><surname>Bayless</surname> <given-names>TM</given-names></name><name><surname>Brand</surname> <given-names>S</given-names></name><name><surname>B√ºning</surname> <given-names>C</given-names></name><name><surname>Cohen</surname> <given-names>A</given-names></name><name><surname>Colombel</surname> <given-names>JF</given-names></name><name><surname>Cottone</surname> <given-names>M</given-names></name><name><surname>Stronati</surname> <given-names>L</given-names></name><name><surname>Denson</surname> <given-names>T</given-names></name><name><surname>De Vos</surname> <given-names>M</given-names></name><name><surname>D'Inca</surname> <given-names>R</given-names></name><name><surname>Dubinsky</surname> <given-names>M</given-names></name><name><surname>Edwards</surname> <given-names>C</given-names></name><name><surname>Florin</surname> <given-names>T</given-names></name><name><surname>Franchimont</surname> <given-names>D</given-names></name><name><surname>Gearry</surname> <given-names>R</given-names></name><name><surname>Glas</surname> <given-names>J</given-names></name><name><surname>Van Gossum</surname> <given-names>A</given-names></name><name><surname>Guthery</surname> <given-names>SL</given-names></name><name><surname>Halfvarson</surname> <given-names>J</given-names></name><name><surname>Verspaget</surname> <given-names>HW</given-names></name><name><surname>Hugot</surname> <given-names>JP</given-names></name><name><surname>Karban</surname> <given-names>A</given-names></name><name><surname>Laukens</surname> <given-names>D</given-names></name><name><surname>Lawrance</surname> <given-names>I</given-names></name><name><surname>Lemann</surname> <given-names>M</given-names></name><name><surname>Levine</surname> <given-names>A</given-names></name><name><surname>Libioulle</surname> <given-names>C</given-names></name><name><surname>Louis</surname> <given-names>E</given-names></name><name><surname>Mowat</surname> <given-names>C</given-names></name><name><surname>Newman</surname> <given-names>W</given-names></name><name><surname>Pan√©s</surname> <given-names>J</given-names></name><name><surname>Phillips</surname> <given-names>A</given-names></name><name><surname>Proctor</surname> <given-names>DD</given-names></name><name><surname>Regueiro</surname> <given-names>M</given-names></name><name><surname>Russell</surname> <given-names>R</given-names></name><name><surname>Rutgeerts</surname> <given-names>P</given-names></name><name><surname>Sanderson</surname> <given-names>J</given-names></name><name><surname>Sans</surname> <given-names>M</given-names></name><name><surname>Seibold</surname> <given-names>F</given-names></name><name><surname>Steinhart</surname> <given-names>AH</given-names></name><name><surname>Stokkers</surname> <given-names>PC</given-names></name><name><surname>Torkvist</surname> <given-names>L</given-names></name><name><surname>Kullak-Ublick</surname> <given-names>G</given-names></name><name><surname>Wilson</surname> <given-names>D</given-names></name><name><surname>Walters</surname> <given-names>T</given-names></name><name><surname>Targan</surname> <given-names>SR</given-names></name><name><surname>Brant</surname> <given-names>SR</given-names></name><name><surname>Rioux</surname> <given-names>JD</given-names></name><name><surname>D'Amato</surname> <given-names>M</given-names></name><name><surname>Weersma</surname> <given-names>RK</given-names></name><name><surname>Kugathasan</surname> <given-names>S</given-names></name><name><surname>Griffiths</surname> <given-names>AM</given-names></name><name><surname>Mansfield</surname> <given-names>JC</given-names></name><name><surname>Vermeire</surname> <given-names>S</given-names></name><name><surname>Duerr</surname> <given-names>RH</given-names></name><name><surname>Silverberg</surname> <given-names>MS</given-names></name><name><surname>Satsangi</surname> <given-names>J</given-names></name><name><surname>Schreiber</surname> <given-names>S</given-names></name><name><surname>Cho</surname> <given-names>JH</given-names></name><name><surname>Annese</surname> <given-names>V</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Parkes</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci</article-title><source>Nature Genetics</source><volume>42</volume><fpage>1118</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1038/ng.717</pub-id><pub-id pub-id-type="pmid">21102463</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraschilla</surname> <given-names>I</given-names></name><name><surname>Jeffrey</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Special issue: molecular mechanisms of Immunity the speckled protein (SP) Family: immunity's Chromatin Readers</article-title><source>Trends in Immunology</source><volume>41</volume><fpage>572</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.04.007</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon√ßalves</surname> <given-names>AV</given-names></name><name><surname>Margolis</surname> <given-names>SR</given-names></name><name><surname>Quirino</surname> <given-names>GFS</given-names></name><name><surname>Mascarenhas</surname> <given-names>DPA</given-names></name><name><surname>Rauch</surname> <given-names>I</given-names></name><name><surname>Nichols</surname> <given-names>RD</given-names></name><name><surname>Ansaldo</surname> <given-names>E</given-names></name><name><surname>Fontana</surname> <given-names>MF</given-names></name><name><surname>Vance</surname> <given-names>RE</given-names></name><name><surname>Zamboni</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gasdermin-D and Caspase-7 are the key Caspase-1/8 substrates downstream of the NAIP5/NLRC4 inflammasome required for restriction of Legionella pneumophila</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007886</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007886</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname> <given-names>J</given-names></name><name><surname>Skerry</surname> <given-names>C</given-names></name><name><surname>Davis</surname> <given-names>SL</given-names></name><name><surname>Tasneen</surname> <given-names>R</given-names></name><name><surname>Weir</surname> <given-names>M</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name><name><surname>Bishai</surname> <given-names>WR</given-names></name><name><surname>Pomper</surname> <given-names>MG</given-names></name><name><surname>Nuermberger</surname> <given-names>EL</given-names></name><name><surname>Jain</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions</article-title><source>The Journal of Infectious Diseases</source><volume>205</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir786</pub-id><pub-id pub-id-type="pmid">22198962</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Berland</surname> <given-names>R</given-names></name><name><surname>Mekasha</surname> <given-names>S</given-names></name><name><surname>Christensen</surname> <given-names>TG</given-names></name><name><surname>Alroy</surname> <given-names>J</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name><name><surname>Ingalls</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The sst1 resistance locus regulates evasion of type I interferon signaling by Chlamydia pneumoniae as a disease tolerance mechanism</article-title><source>PLOS Pathogens</source><volume>9</volume><elocation-id>e1003569</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003569</pub-id><pub-id pub-id-type="pmid">24009502</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huoh</surname> <given-names>YS</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Park</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Bansal</surname> <given-names>K</given-names></name><name><surname>Greenwald</surname> <given-names>E</given-names></name><name><surname>Wong</surname> <given-names>WP</given-names></name><name><surname>Mathis</surname> <given-names>D</given-names></name><name><surname>Hur</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dual functions of aire CARD multimerization in the transcriptional regulation of T cell tolerance</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1625</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15448-w</pub-id><pub-id pub-id-type="pmid">32242017</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International IBD Genetics Consortium (IIBDGC)</collab><name><surname>Jostins</surname> <given-names>L</given-names></name><name><surname>Ripke</surname> <given-names>S</given-names></name><name><surname>Weersma</surname> <given-names>RK</given-names></name><name><surname>Duerr</surname> <given-names>RH</given-names></name><name><surname>McGovern</surname> <given-names>DP</given-names></name><name><surname>Hui</surname> <given-names>KY</given-names></name><name><surname>Lee</surname> <given-names>JC</given-names></name><name><surname>Schumm</surname> <given-names>LP</given-names></name><name><surname>Sharma</surname> <given-names>Y</given-names></name><name><surname>Anderson</surname> <given-names>CA</given-names></name><name><surname>Essers</surname> <given-names>J</given-names></name><name><surname>Mitrovic</surname> <given-names>M</given-names></name><name><surname>Ning</surname> <given-names>K</given-names></name><name><surname>Cleynen</surname> <given-names>I</given-names></name><name><surname>Theatre</surname> <given-names>E</given-names></name><name><surname>Spain</surname> <given-names>SL</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Goyette</surname> <given-names>P</given-names></name><name><surname>Wei</surname> <given-names>Z</given-names></name><name><surname>Abraham</surname> <given-names>C</given-names></name><name><surname>Achkar</surname> <given-names>JP</given-names></name><name><surname>Ahmad</surname> <given-names>T</given-names></name><name><surname>Amininejad</surname> <given-names>L</given-names></name><name><surname>Ananthakrishnan</surname> <given-names>AN</given-names></name><name><surname>Andersen</surname> <given-names>V</given-names></name><name><surname>Andrews</surname> <given-names>JM</given-names></name><name><surname>Baidoo</surname> <given-names>L</given-names></name><name><surname>Balschun</surname> <given-names>T</given-names></name><name><surname>Bampton</surname> <given-names>PA</given-names></name><name><surname>Bitton</surname> <given-names>A</given-names></name><name><surname>Boucher</surname> <given-names>G</given-names></name><name><surname>Brand</surname> <given-names>S</given-names></name><name><surname>B√ºning</surname> <given-names>C</given-names></name><name><surname>Cohain</surname> <given-names>A</given-names></name><name><surname>Cichon</surname> <given-names>S</given-names></name><name><surname>D'Amato</surname> <given-names>M</given-names></name><name><surname>De Jong</surname> <given-names>D</given-names></name><name><surname>Devaney</surname> <given-names>KL</given-names></name><name><surname>Dubinsky</surname> <given-names>M</given-names></name><name><surname>Edwards</surname> <given-names>C</given-names></name><name><surname>Ellinghaus</surname> <given-names>D</given-names></name><name><surname>Ferguson</surname> <given-names>LR</given-names></name><name><surname>Franchimont</surname> <given-names>D</given-names></name><name><surname>Fransen</surname> <given-names>K</given-names></name><name><surname>Gearry</surname> <given-names>R</given-names></name><name><surname>Georges</surname> <given-names>M</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Glas</surname> <given-names>J</given-names></name><name><surname>Haritunians</surname> <given-names>T</given-names></name><name><surname>Hart</surname> <given-names>A</given-names></name><name><surname>Hawkey</surname> <given-names>C</given-names></name><name><surname>Hedl</surname> <given-names>M</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Karlsen</surname> <given-names>TH</given-names></name><name><surname>Kupcinskas</surname> <given-names>L</given-names></name><name><surname>Kugathasan</surname> <given-names>S</given-names></name><name><surname>Latiano</surname> <given-names>A</given-names></name><name><surname>Laukens</surname> <given-names>D</given-names></name><name><surname>Lawrance</surname> <given-names>IC</given-names></name><name><surname>Lees</surname> <given-names>CW</given-names></name><name><surname>Louis</surname> <given-names>E</given-names></name><name><surname>Mahy</surname> <given-names>G</given-names></name><name><surname>Mansfield</surname> <given-names>J</given-names></name><name><surname>Morgan</surname> <given-names>AR</given-names></name><name><surname>Mowat</surname> <given-names>C</given-names></name><name><surname>Newman</surname> <given-names>W</given-names></name><name><surname>Palmieri</surname> <given-names>O</given-names></name><name><surname>Ponsioen</surname> <given-names>CY</given-names></name><name><surname>Potocnik</surname> <given-names>U</given-names></name><name><surname>Prescott</surname> <given-names>NJ</given-names></name><name><surname>Regueiro</surname> <given-names>M</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Russell</surname> <given-names>RK</given-names></name><name><surname>Sanderson</surname> <given-names>JD</given-names></name><name><surname>Sans</surname> <given-names>M</given-names></name><name><surname>Satsangi</surname> <given-names>J</given-names></name><name><surname>Schreiber</surname> <given-names>S</given-names></name><name><surname>Simms</surname> <given-names>LA</given-names></name><name><surname>Sventoraityte</surname> <given-names>J</given-names></name><name><surname>Targan</surname> <given-names>SR</given-names></name><name><surname>Taylor</surname> <given-names>KD</given-names></name><name><surname>Tremelling</surname> <given-names>M</given-names></name><name><surname>Verspaget</surname> <given-names>HW</given-names></name><name><surname>De Vos</surname> <given-names>M</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Wilson</surname> <given-names>DC</given-names></name><name><surname>Winkelmann</surname> <given-names>J</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Zeissig</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>CK</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Silverberg</surname> <given-names>MS</given-names></name><name><surname>Annese</surname> <given-names>V</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Brant</surname> <given-names>SR</given-names></name><name><surname>Radford-Smith</surname> <given-names>G</given-names></name><name><surname>Mathew</surname> <given-names>CG</given-names></name><name><surname>Rioux</surname> <given-names>JD</given-names></name><name><surname>Schadt</surname> <given-names>EE</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Franke</surname> <given-names>A</given-names></name><name><surname>Parkes</surname> <given-names>M</given-names></name><name><surname>Vermeire</surname> <given-names>S</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name><name><surname>Cho</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease</article-title><source>Nature</source><volume>491</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/nature11582</pub-id><pub-id pub-id-type="pmid">23128233</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname> <given-names>DX</given-names></name><name><surname>Yamashiro</surname> <given-names>LH</given-names></name><name><surname>Chen</surname> <given-names>KJ</given-names></name><name><surname>Mukaida</surname> <given-names>N</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name><name><surname>Darwin</surname> <given-names>KH</given-names></name><name><surname>Vance</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra</article-title><source>Nature Microbiology</source><volume>4</volume><fpage>2128</fpage><lpage>2135</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0578-3</pub-id><pub-id pub-id-type="pmid">31611644</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaky</surname> <given-names>M</given-names></name><name><surname>Fedetz</surname> <given-names>M</given-names></name><name><surname>Potenciano</surname> <given-names>V</given-names></name><name><surname>Andr√©s-Le√≥n</surname> <given-names>E</given-names></name><name><surname>Codina</surname> <given-names>AE</given-names></name><name><surname>Barrionuevo</surname> <given-names>C</given-names></name><name><surname>Alcina</surname> <given-names>A</given-names></name><name><surname>Matesanz</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SP140 regulates the expression of immune-related genes associated with multiple sclerosis and other autoimmune diseases by NF-kappaB inhibition</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>4012</fpage><lpage>4023</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy284</pub-id><pub-id pub-id-type="pmid">30102396</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname> <given-names>X</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Zha</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>SP110 gene polymorphisms and tuberculosis susceptibility: a systematic review and meta-analysis based on 10 624 subjects</article-title><source>Infection, Genetics and Evolution</source><volume>12</volume><fpage>1473</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2012.05.011</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Handsaker</surname> <given-names>B</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Ruan</surname> <given-names>J</given-names></name><name><surname>Homer</surname> <given-names>N</given-names></name><name><surname>Marth</surname> <given-names>G</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1303.3997">http://arxiv.org/abs/1303.3997</ext-link></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="pmid">19451168</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locksley</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Th2 cells: help for helminths</article-title><source>Journal of Experimental Medicine</source><volume>179</volume><fpage>1405</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1084/jem.179.5.1405</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname> <given-names>A</given-names></name><name><surname>Dinarello</surname> <given-names>CA</given-names></name><name><surname>Molgora</surname> <given-names>M</given-names></name><name><surname>Garlanda</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interleukin-1 and related cytokines in the regulation of inflammation and immunity</article-title><source>Immunity</source><volume>50</volume><fpage>778</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.012</pub-id><pub-id pub-id-type="pmid">30995499</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascarenhas</surname> <given-names>DPA</given-names></name><name><surname>Pereira</surname> <given-names>MSF</given-names></name><name><surname>Manin</surname> <given-names>GZ</given-names></name><name><surname>Hori</surname> <given-names>JI</given-names></name><name><surname>Zamboni</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interleukin 1 Receptor‚ÄìDriven Neutrophil Recruitment Accounts to MyD88‚ÄìDependent Pulmonary Clearance of <italic>Legionella pneumophila</italic> Infection In Vivo</article-title><source>Journal of Infectious Diseases</source><volume>211</volume><fpage>322</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu430</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matesanz</surname> <given-names>F</given-names></name><name><surname>Potenciano</surname> <given-names>V</given-names></name><name><surname>Fedetz</surname> <given-names>M</given-names></name><name><surname>Ramos-Mozo</surname> <given-names>P</given-names></name><name><surname>Abad-Grau</surname> <given-names>MM</given-names></name><name><surname>Karaky</surname> <given-names>M</given-names></name><name><surname>Barrionuevo</surname> <given-names>C</given-names></name><name><surname>Izquierdo</surname> <given-names>G</given-names></name><name><surname>Ruiz-Pe√±a</surname> <given-names>JL</given-names></name><name><surname>Garc√≠a-S√°nchez</surname> <given-names>MI</given-names></name><name><surname>Lucas</surname> <given-names>M</given-names></name><name><surname>Fern√°ndez</surname> <given-names>√ì</given-names></name><name><surname>Leyva</surname> <given-names>L</given-names></name><name><surname>Otaegui</surname> <given-names>D</given-names></name><name><surname>Mu√±oz-Culla</surname> <given-names>M</given-names></name><name><surname>Olascoaga</surname> <given-names>J</given-names></name><name><surname>Vandenbroeck</surname> <given-names>K</given-names></name><name><surname>Alloza</surname> <given-names>I</given-names></name><name><surname>Astobiza</surname> <given-names>I</given-names></name><name><surname>Antig√ºedad</surname> <given-names>A</given-names></name><name><surname>Villar</surname> <given-names>LM</given-names></name><name><surname>√Ålvarez-Cerme√±o</surname> <given-names>JC</given-names></name><name><surname>Malhotra</surname> <given-names>S</given-names></name><name><surname>Comabella</surname> <given-names>M</given-names></name><name><surname>Montalban</surname> <given-names>X</given-names></name><name><surname>Saiz</surname> <given-names>A</given-names></name><name><surname>Blanco</surname> <given-names>Y</given-names></name><name><surname>Arroyo</surname> <given-names>R</given-names></name><name><surname>Varad√©</surname> <given-names>J</given-names></name><name><surname>Urcelay</surname> <given-names>E</given-names></name><name><surname>Alcina</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A functional variant that affects exon-skipping and protein expression of <italic>SP140</italic> as genetic mechanism predisposing to multiple sclerosis</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>5619</fpage><lpage>5627</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv256</pub-id><pub-id pub-id-type="pmid">26152201</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname> <given-names>KD</given-names></name><name><surname>Andrade</surname> <given-names>BB</given-names></name><name><surname>Oland</surname> <given-names>SD</given-names></name><name><surname>Amaral</surname> <given-names>EP</given-names></name><name><surname>Barber</surname> <given-names>DL</given-names></name><name><surname>Gonzales</surname> <given-names>J</given-names></name><name><surname>Derrick</surname> <given-names>SC</given-names></name><name><surname>Shi</surname> <given-names>R</given-names></name><name><surname>Kumar</surname> <given-names>NP</given-names></name><name><surname>Wei</surname> <given-names>W</given-names></name><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Cai</surname> <given-names>Y</given-names></name><name><surname>Babu</surname> <given-names>S</given-names></name><name><surname>Catalfamo</surname> <given-names>M</given-names></name><name><surname>Salazar</surname> <given-names>AM</given-names></name><name><surname>Via</surname> <given-names>LE</given-names></name><name><surname>Barry</surname> <given-names>CE</given-names></name><name><surname>Sher</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk</article-title><source>Nature</source><volume>511</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nature13489</pub-id><pub-id pub-id-type="pmid">24990750</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNab</surname> <given-names>F</given-names></name><name><surname>Mayer-Barber</surname> <given-names>K</given-names></name><name><surname>Sher</surname> <given-names>A</given-names></name><name><surname>Wack</surname> <given-names>A</given-names></name><name><surname>O'Garra</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Type I interferons in infectious disease</article-title><source>Nature Reviews Immunology</source><volume>15</volume><fpage>87</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nri3787</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname> <given-names>S</given-names></name><name><surname>Cronkite</surname> <given-names>DA</given-names></name><name><surname>Basavappa</surname> <given-names>M</given-names></name><name><surname>Saunders</surname> <given-names>TL</given-names></name><name><surname>Adiliaghdam</surname> <given-names>F</given-names></name><name><surname>Amatullah</surname> <given-names>H</given-names></name><name><surname>Morrison</surname> <given-names>SA</given-names></name><name><surname>Pagan</surname> <given-names>JD</given-names></name><name><surname>Anthony</surname> <given-names>RM</given-names></name><name><surname>Tonnerre</surname> <given-names>P</given-names></name><name><surname>Lauer</surname> <given-names>GM</given-names></name><name><surname>Lee</surname> <given-names>JC</given-names></name><name><surname>Digumarthi</surname> <given-names>S</given-names></name><name><surname>Pantano</surname> <given-names>L</given-names></name><name><surname>Ho Sui</surname> <given-names>SJ</given-names></name><name><surname>Ji</surname> <given-names>F</given-names></name><name><surname>Sadreyev</surname> <given-names>R</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Mullen</surname> <given-names>AC</given-names></name><name><surname>Kumar</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Means</surname> <given-names>TK</given-names></name><name><surname>Jeffrey</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140</article-title><source>Science Immunology</source><volume>2</volume><elocation-id>eaag3160</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aag3160</pub-id><pub-id pub-id-type="pmid">28783698</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira-Teixeira</surname> <given-names>L</given-names></name><name><surname>Mayer-Barber</surname> <given-names>K</given-names></name><name><surname>Sher</surname> <given-names>A</given-names></name><name><surname>O‚ÄôGarra</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Type I interferons in tuberculosis: foe and occasionally friend</article-title><source>Journal of Experimental Medicine</source><volume>215</volume><fpage>1273</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1084/jem.20180325</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connell</surname> <given-names>RM</given-names></name><name><surname>Saha</surname> <given-names>SK</given-names></name><name><surname>Vaidya</surname> <given-names>SA</given-names></name><name><surname>Bruhn</surname> <given-names>KW</given-names></name><name><surname>Miranda</surname> <given-names>GA</given-names></name><name><surname>Zarnegar</surname> <given-names>B</given-names></name><name><surname>Perry</surname> <given-names>AK</given-names></name><name><surname>Nguyen</surname> <given-names>BO</given-names></name><name><surname>Lane</surname> <given-names>TF</given-names></name><name><surname>Taniguchi</surname> <given-names>T</given-names></name><name><surname>Miller</surname> <given-names>JF</given-names></name><name><surname>Cheng</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Type I interferon production enhances susceptibility to Listeria monocytogenes infection</article-title><source>Journal of Experimental Medicine</source><volume>200</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1084/jem.20040712</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Yan</surname> <given-names>BS</given-names></name><name><surname>Rojas</surname> <given-names>M</given-names></name><name><surname>Shebzukhov</surname> <given-names>YV</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Kobzik</surname> <given-names>L</given-names></name><name><surname>Higgins</surname> <given-names>DE</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Bloom</surname> <given-names>BR</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Ipr1 gene mediates innate immunity to tuberculosis</article-title><source>Nature</source><volume>434</volume><fpage>767</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1038/nature03419</pub-id><pub-id pub-id-type="pmid">15815631</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perniola</surname> <given-names>R</given-names></name><name><surname>Musco</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The biophysical and biochemical properties of the autoimmune regulator (AIRE) protein</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease</source><volume>1842</volume><fpage>326</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2013.11.020</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichugin</surname> <given-names>AV</given-names></name><name><surname>Yan</surname> <given-names>BS</given-names></name><name><surname>Sloutsky</surname> <given-names>A</given-names></name><name><surname>Kobzik</surname> <given-names>L</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts</article-title><source>The American Journal of Pathology</source><volume>174</volume><fpage>2190</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2009.081075</pub-id><pub-id pub-id-type="pmid">19443700</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilla-Moffett</surname> <given-names>D</given-names></name><name><surname>Barber</surname> <given-names>MF</given-names></name><name><surname>Taylor</surname> <given-names>GA</given-names></name><name><surname>Coers</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Interferon-Inducible GTPases in host resistance, inflammation and disease</article-title><source>Journal of Molecular Biology</source><volume>428</volume><fpage>3495</fpage><lpage>3513</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2016.04.032</pub-id><pub-id pub-id-type="pmid">27181197</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Bray</surname> <given-names>NL</given-names></name><name><surname>Puente</surname> <given-names>S</given-names></name><name><surname>Melsted</surname> <given-names>P</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differential analysis of RNA-seq incorporating quantification uncertainty</article-title><source>Nature Methods</source><volume>14</volume><fpage>687</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4324</pub-id><pub-id pub-id-type="pmid">28581496</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Png</surname> <given-names>E</given-names></name><name><surname>Alisjahbana</surname> <given-names>B</given-names></name><name><surname>Sahiratmadja</surname> <given-names>E</given-names></name><name><surname>Marzuki</surname> <given-names>S</given-names></name><name><surname>Nelwan</surname> <given-names>R</given-names></name><name><surname>Adnan</surname> <given-names>I</given-names></name><name><surname>van de Vosse</surname> <given-names>E</given-names></name><name><surname>Hibberd</surname> <given-names>M</given-names></name><name><surname>van Crevel</surname> <given-names>R</given-names></name><name><surname>Ottenhoff</surname> <given-names>THM</given-names></name><name><surname>Seielstad</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Polymorphisms in SP110 are not associated with pulmonary tuberculosis in indonesians</article-title><source>Infection, Genetics and Evolution</source><volume>12</volume><fpage>1319</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2012.04.006</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname> <given-names>A</given-names></name><name><surname>Caciula</surname> <given-names>A</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>B</given-names></name><name><surname>Morrison</surname> <given-names>J</given-names></name><name><surname>Rasmussen</surname> <given-names>A</given-names></name><name><surname>Lipkin</surname> <given-names>WI</given-names></name><name><surname>Jain</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>DEvis: an R package for aggregation and visualization of differential expression data</article-title><source>BMC Bioinformatics</source><volume>20</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-019-2702-z</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayamajhi</surname> <given-names>M</given-names></name><name><surname>Humann</surname> <given-names>J</given-names></name><name><surname>Penheiter</surname> <given-names>K</given-names></name><name><surname>Andreasen</surname> <given-names>K</given-names></name><name><surname>Lenz</surname> <given-names>LL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Induction of IFN-Œ±Œ≤ enables Listeria monocytogenes to suppress macrophage activation by IFN-Œ≥</article-title><source>Journal of Experimental Medicine</source><volume>207</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1084/jem.20091746</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roscioli</surname> <given-names>T</given-names></name><name><surname>Cliffe</surname> <given-names>ST</given-names></name><name><surname>Bloch</surname> <given-names>DB</given-names></name><name><surname>Bell</surname> <given-names>CG</given-names></name><name><surname>Mullan</surname> <given-names>G</given-names></name><name><surname>Taylor</surname> <given-names>PJ</given-names></name><name><surname>Sarris</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Donald</surname> <given-names>JA</given-names></name><name><surname>Kirk</surname> <given-names>EP</given-names></name><name><surname>Ziegler</surname> <given-names>JB</given-names></name><name><surname>Salzer</surname> <given-names>U</given-names></name><name><surname>McDonald</surname> <given-names>GB</given-names></name><name><surname>Wong</surname> <given-names>M</given-names></name><name><surname>Lindeman</surname> <given-names>R</given-names></name><name><surname>Buckley</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease</article-title><source>Nature Genetics</source><volume>38</volume><fpage>620</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/ng1780</pub-id><pub-id pub-id-type="pmid">16648851</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherer</surname> <given-names>M</given-names></name><name><surname>Stamminger</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emerging role of PML nuclear bodies in innate immune signaling</article-title><source>Journal of Virology</source><volume>90</volume><fpage>5850</fpage><lpage>5854</lpage><pub-id pub-id-type="doi">10.1128/JVI.01979-15</pub-id><pub-id pub-id-type="pmid">27053550</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname> <given-names>T</given-names></name><name><surname>Schmid-Burgk</surname> <given-names>JL</given-names></name><name><surname>Hornung</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synthesis of an arrayed sgRNA library targeting the human genome OPEN</article-title><source>Nature Publishing Group</source><volume>5</volume><elocation-id>14987</elocation-id><pub-id pub-id-type="doi">10.1038/srep14987</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname> <given-names>WM</given-names></name><name><surname>Chevillotte</surname> <given-names>MD</given-names></name><name><surname>Rice</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interferon-stimulated genes: a complex web of host defenses</article-title><source>Annual Review of Immunology</source><volume>32</volume><fpage>513</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id><pub-id pub-id-type="pmid">24555472</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>W</given-names></name><name><surname>Le</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SeqKit: a Cross-Platform and ultrafast toolkit for FASTA/Q file manipulation</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0163962</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0163962</pub-id><pub-id pub-id-type="pmid">27706213</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slager</surname> <given-names>SL</given-names></name><name><surname>Caporaso</surname> <given-names>NE</given-names></name><name><surname>de Sanjose</surname> <given-names>S</given-names></name><name><surname>Goldin</surname> <given-names>LR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetic susceptibility to chronic lymphocytic leukemia</article-title><source>Seminars in Hematology</source><volume>50</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1053/j.seminhematol.2013.09.007</pub-id><pub-id pub-id-type="pmid">24246697</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stetson</surname> <given-names>DB</given-names></name><name><surname>Medzhitov</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Type I interferons in host defense</article-title><source>Immunity</source><volume>25</volume><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.007</pub-id><pub-id pub-id-type="pmid">16979569</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thye</surname> <given-names>T</given-names></name><name><surname>Browne</surname> <given-names>EN</given-names></name><name><surname>Chinbuah</surname> <given-names>MA</given-names></name><name><surname>Gyapong</surname> <given-names>J</given-names></name><name><surname>Osei</surname> <given-names>I</given-names></name><name><surname>Owusu-Dabo</surname> <given-names>E</given-names></name><name><surname>Niemann</surname> <given-names>S</given-names></name><name><surname>R√ºsch-Gerdes</surname> <given-names>S</given-names></name><name><surname>Horstmann</surname> <given-names>RD</given-names></name><name><surname>Meyer</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>No associations of human pulmonary tuberculosis with Sp110 variants</article-title><source>Journal of Medical Genetics</source><volume>43</volume><elocation-id>e32</elocation-id><pub-id pub-id-type="doi">10.1136/jmg.2005.037960</pub-id><pub-id pub-id-type="pmid">16816019</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosh</surname> <given-names>K</given-names></name><name><surname>Campbell</surname> <given-names>SJ</given-names></name><name><surname>Fielding</surname> <given-names>K</given-names></name><name><surname>Sillah</surname> <given-names>J</given-names></name><name><surname>Bah</surname> <given-names>B</given-names></name><name><surname>Gustafson</surname> <given-names>P</given-names></name><name><surname>Manneh</surname> <given-names>K</given-names></name><name><surname>Lisse</surname> <given-names>I</given-names></name><name><surname>Sirugo</surname> <given-names>G</given-names></name><name><surname>Bennett</surname> <given-names>S</given-names></name><name><surname>Aaby</surname> <given-names>P</given-names></name><name><surname>McAdam</surname> <given-names>K</given-names></name><name><surname>Bah-Sow</surname> <given-names>O</given-names></name><name><surname>Lienhardt</surname> <given-names>C</given-names></name><name><surname>Kramnik</surname> <given-names>I</given-names></name><name><surname>Hill</surname> <given-names>AVS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in west africa</article-title><source>PNAS</source><volume>103</volume><fpage>10364</fpage><lpage>10368</lpage><pub-id pub-id-type="doi">10.1073/pnas.0603340103</pub-id><pub-id pub-id-type="pmid">16803959</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Shivalila</surname> <given-names>CS</given-names></name><name><surname>Dawlaty</surname> <given-names>MM</given-names></name><name><surname>Cheng</surname> <given-names>AW</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>One-Step generation of mice carrying mutations in multiple genes by CRISPR/Cas-Mediated genome engineering</article-title><source>Cell</source><volume>153</volume><fpage>910</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.025</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weichenhan</surname> <given-names>D</given-names></name><name><surname>Kunze</surname> <given-names>B</given-names></name><name><surname>Winking</surname> <given-names>H</given-names></name><name><surname>van Geel</surname> <given-names>M</given-names></name><name><surname>Osoegawa</surname> <given-names>K</given-names></name><name><surname>de Jong</surname> <given-names>PJ</given-names></name><name><surname>Traut</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Source and component genes of a 6-200 mb gene cluster in the house mouse</article-title><source>Mammalian Genome</source><volume>12</volume><fpage>590</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1007/s00335-001-3015-9</pub-id><pub-id pub-id-type="pmid">11471051</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>XB</given-names></name><name><surname>Han</surname> <given-names>YD</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Zheng</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Certain polymorphisms in SP110 gene confer susceptibility to tuberculosis: a comprehensive review and updated Meta-Analysis</article-title><source>Yonsei Medical Journal</source><volume>58</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.3349/ymj.2017.58.1.165</pub-id><pub-id pub-id-type="pmid">27873510</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>A</given-names></name><name><surname>Ibrahim</surname> <given-names>JG</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences</article-title><source>Bioinformatics</source><volume>35</volume><fpage>2084</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty895</pub-id><pub-id pub-id-type="pmid">30395178</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67290.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Stallings</surname><given-names>Christina L</given-names></name><role>Reviewing Editor</role><aff><institution>Washington University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>In this revised manuscript the authors' have addressed the reviewers' comments regarding this important and well-executed study into genetic factors that impact susceptibility to bacterial infections. Specifically, the authors identify the gene SP140 as the driving mutation resulting in susceptibility to a range of bacterial pathogens located within the severe susceptibility to tuberculosis (SST1) in mice. While our understanding of how SP140 functions remains unknown, the identification of a single gene within this locus that regulates Type I IFN is impactful and will be of broad interest for immunologists and microbiologists alike.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Role of the transcriptional regulator SP140 in resistance to bacterial infections via repression of type I interferons&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Satyajit Rath as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The reviewers all agree that this is an important manuscript that would benefit from more thorough comparisons between Sp110-/-, Sp140-/-, and Sst1S mice. Specifically:</p><p>1) While the authors show many phenotypes of the Sst1S mouse are recapitulated in the Sp140-/- they did not fully compare them. For example, do the Sp140-/- mice/macrophages have increased necrosis and cell death during Mtb infection or following TNF stimulation? Are any of the lesions hypoxic? The pathology comparisons seem relatively superficial and could be quantified and examined more in depth to convincingly claim the effects of the Sst1S mice are recapitulated. In general, a more thorough histological analysis with more sections throughout the manuscript would be beneficial and aid in quantification. Particularly since this is a key feature of the Sst1S mice.</p><p>2) In Figure 3A, the Sp140-/- mice appear to drive even more type I IFN than Sst1 animals. Is this difference significant? How do the authors interpret these findings?</p><p>3) In Figure 2, the figure could be better labeled to distinguish A and B with RNA vs Protein. Additionally, the authors say &quot;untreated nor IFNŒ≥ treated BMDMs produce SP140&quot; but the data appear to only show IFNŒ≥ treated. This should clarified and/or the data shown.</p><p>4) The RNAseq experiments were performed with only two replicates, whereas at least 3 would be standard for these analyses.</p><p>5) The authors mention that they did not observe a consistent difference between the Sp140-/- and Sst1S mice, however, these strains are not completely overlapping in the expression profiling analysis. This could be because Sst1S has some expression of Sp140, whereas the KO has none, but this should be discussed. It would also be helpful to include WT B6 in the heatmaps in 4C and D.</p><p>6) In Figure 2, the levels of Sp140 protein in the Sp110-/- mice should be included in panel B to show that protein expression is intact (not just transcript) to rule out epistatic effects of missing both Sp140 and Sp110.</p><p><italic>Reviewer #1:</italic></p><p>In this manuscript, the authors build off their previous data where they have identified differences in the sst1 locus as responsible for differences in susceptibility of B6 and C3HeB/Fej mice to <italic>Mycobacterium tuberculosis</italic> infection. The authors have previously shown that this susceptibility is attributed to higher levels of type I IFN signaling and in particular, the ISG IL-1Ra. The sst1 locus contains many genes that could be contributing to the differential susceptibility in C3HeB/Fej mice, and the model in the field was that differences in Sp110 expression was a likely candidate to explain the susceptibility. However, in this manuscript, the authors show that it is not lower expression of Sp110, but instead decreased expression of another gene in the sst1 locus, Sp140, that contributes to the increased susceptibility of mice carrying the sst1S sequence to bacterial infections. This is a very significant and surprising finding, supported by very clear and convincing data from experiments performed with a high level of rigor. Although identification of the gene responsible for differences in susceptibility and outcomes during bacterial infections is an advance for the field, the manuscript stops there in terms of new insight and falls short of providing any additional information beyond what has already been published regarding how this gene or lucus is functioning to regulate immune responses to infection. This limited scope embodies the major concern for this otherwise strong manuscript.</p><p><italic>Reviewer #2:</italic></p><p>The authors have suggested the importance of SP140 for resistance to Mtb, Legionella infections in mice. They also provide evidence for IFNaR signalling in mediating the increased susceptibility of SP140-/- mice. While they attribute an important function of the transcriptional regulator SP140 to regulation of type I IFN responses by demonstrating the dysregulation of these responses in the SP140-/- mice, more direct evidence for this is needed.</p><p><italic>Reviewer #3:</italic></p><p>In this manuscript Ji et al. carefully examine candidate genes driving a previously described susceptibility within the severe susceptibility to tuberculosis (sst1). Surprisingly, mice deficient in the original candidate gene within this locus, SP110, showed no change in susceptibility to infection with <italic>M. tuberculosis</italic>. In contrast, the authors found that loss of a second gene in this locus, SP140, recapitulated many phenotypes seen in the SST1 mouse, including increased Type I IFN. SP140 susceptibility was reversed by blocking these exacerbated type I IFNs, similar to SST1 mice. RNAseq analysis identify changes in pro-inflammatory cytokines and type I IFNs. The strengths of this paper are the careful and controlled experiments to target and analyze mouse mutants within a notoriously challenging region with homopolymers. Their results are robust, convincing and will be of broad interest to the field of immunology and host-pathogen interactions. Convincingly identifying a single gene within this region that recapitulates many aspects of the SST1 mouse is very important. While a minor weakness is the lack of any mechanistic understanding of how SP140 functions, this is overcome by the impact of the other findings and it is anticipated that this mouse will now be a key resource to dissect the mechanisms of susceptibility in much greater detail.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67290.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The reviewers all agree that this is an important manuscript that would benefit from more thorough comparisons between Sp110-/-, Sp140-/-, and Sst1S mice. Specifically:</p><p>1) While the authors show many phenotypes of the Sst1S mouse are recapitulated in the Sp140-/- they did not fully compare them. For example, do the Sp140-/- mice/macrophages have increased necrosis and cell death during Mtb infection or following TNF stimulation? Are any of the lesions hypoxic?</p></disp-quote><p>The lesions observed in our histology samples are not hypoxic, since these samples are taken at a timepoint before hypoxia develops (Harper et al. (2012) PMC3266133). Importantly, we do not believe that hypoxia is the key to the susceptibility phenotype of these mice since we can see increased bacterial burdens before the mice reach the point at which the lesions become hypoxic. Our focus has been on the early immunological phenotypes that contribute to elevated CFU burdens. Others in the field may be interested in pursuing the hypoxia phenotype but this is not the focus of our paper. Hypoxia is also technically challenging to pursue since it only emerges at late timepoints. Similarly, we are not convinced that the cell death exhibited by B6.Sst1<sup>S</sup> BMMs is driving the susceptibility of the mice. Indeed, we do not know how to specifically eliminate the cell death response in order to study its importance. For this reason, any discussion of the role of cell death would be purely speculative and thus our manuscript focuses on the hyper type I IFN production seen in both the B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice. Because Ifnar deficiency rescues the susceptibility/CFU burdens of the mice, it is clear that type I IFNs are driving the disease phenotypes, and thus this is the focus of our manuscript. Nevertheless, to satisfy the reviewers, we have now included data in the revised manuscript showing that both B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> BMMs die upon treatment with polyI:C (Figure 3 <bold>‚àí</bold> figure supplement 1, lines 209-216). Importantly, this cell death response is reduced or eliminated by crosses to Ifnar<sup>‚Äì/‚Äì</sup> mice, again emphasizing the primary importance of type I IFNs to the phenotype(s) of these mice.</p><p>We emphasize that we have fully compared CFUs and susceptibility for multiple bacterial infections in vivo, as well as transcriptional changes during <italic>M. tuberculosis</italic> infections in vivo, for both B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice. These mice are essentially indistinguishable in terms of susceptibility to bacterial infection in vivo, and exhibit highly similar transcriptional responses to <italic>M. tuberculosis</italic> infection. As elaborated below, we have also expanded our comparison of lung pathology for B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice. We feel that our studies establish the main claim of the manuscript, which is not that B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice are identical, but rather, that loss of Sp140 is responsible for the susceptibility of Sst1<sup>S</sup> mice to bacterial infections.</p><disp-quote content-type="editor-comment"><p>The pathology comparisons seem relatively superficial and could be quantified and examined more in depth to convincingly claim the effects of the Sst1S mice are recapitulated. In general, a more thorough histological analysis with more sections throughout the manuscript would be beneficial and aid in quantification. Particularly since this is a key feature of the Sst1S mice.</p></disp-quote><p>As argued above, we don‚Äôt necessarily believe that the histopathology seen in Sst1<sup>S</sup> mice is the key to understanding the Sst1<sup>S</sup> phenotype. Again, CFU burdens are clearly elevated in Sp140<sup>‚Äì/‚Äì</sup> mice prior to the development of the highly organized/necrotic/hypoxic lesions, so we tend to think that the advanced features of these lesions are a late downstream consequence of a loss of bacterial control and is not therefore something we decided to focus on. Nevertheless, the point about better characterizing the histology is well taken. We have included a more in-depth analysis of the histology performed by a trained pathologist (newly added author Stephen Nishimura) and included scoring of macrophage, lymphoid, and granulocyte infiltration as well as extent of necrosis, in Figure 2 ‚àí figure supplement 2. We have also expanded our discussion of the histology in the paper (lines 165-173). As discussed above, at the relatively early timepoint analyzed (day 25), we do not observe dramatic differences in histology, but we do observe a trend of increased granulocyte infiltration for both B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> lungs. Disease does appear to be more severe in the Sp140<sup>‚Äì/‚Äì</sup> lungs as compared to Sst1<sup>S</sup> lungs, but we do not wish to overemphasize this, as the differences are not statistically significant, and may be due to a small amount of residual Sp140 function in Sst1<sup>S</sup> mice, or alternatively, due to microbiota differences between the strains. We have expanded our discussion to make these points. Again, our genetic data suggest that type I IFNs are the main driver of the Sst1<sup>S</sup> phenotype and so we have focused our comparison to Sp140<sup>‚Äì/‚Äì</sup> mice on this aspect of the phenotype.</p><disp-quote content-type="editor-comment"><p>2) In Figure 3A, the Sp140-/- mice appear to drive even more type I IFN than Sst1 animals. Is this difference significant? How do the authors interpret these findings?</p></disp-quote><p>This difference is significant and is now clearly marked in the figure and discussed further in the text (lines 219-224). As the reviewers have suggested, this difference could potentially derive from the partial low expression of Sp140 in B6.Sst1<sup>S</sup>, or possibly due to other differences (e.g., expression of Sp110, or microbiota differences) between the strains. We do not believe this difference is of major functional importance as the CFU at this timepoint is indistinguishable for B6.Sst1<sup>S</sup> vs. Sp140<sup>‚Äì/‚Äì</sup>, there are no significant differences in weight loss or survival upon <italic>M. tuberculosis</italic> infection between B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice, and the transcriptomes of both B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> both show an elevated ISG signature upon <italic>M. tuberculosis</italic> infection. Furthermore, the differentially expressed genes between B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> are not annotated as type 1 interferon stimulated genes, and we did not see statistically significant differences in expression for the interferon stimulated gene Il1rn genes between B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice during <italic>M. tuberculosis</italic> infection (Figure 4 ‚àí figure supplement 1). We hypothesize that above a certain threshold, a moderate increase in type I IFN that we observe in Sp140<sup>‚Äì/‚Äì</sup> mice as compared to B6.Sst1<sup>S</sup> mice does not necessarily translate to further increased susceptibility to bacterial infection.</p><disp-quote content-type="editor-comment"><p>3) In Figure 2, the figure could be better labeled to distinguish A and B with RNA vs Protein. Additionally, the authors say &quot;untreated nor IFNŒ≥ treated BMDMs produce SP140&quot; but the data appear to only show IFNŒ≥ treated. This should clarified and/or the data shown.</p></disp-quote><p>The indicated figure and text have been modified for better clarity.</p><disp-quote content-type="editor-comment"><p>4) The RNAseq experiments were performed with only two replicates, whereas at least 3 would be standard for these analyses.</p></disp-quote><p>We recognize the limitations of RNAseq with 2 replicates. However, despite this limitation, our replicates show very similar patterns of gene expression and are sufficient to establish the broad claims we make in the manuscript. We were also able to observe significant differences in expression of numerous ISGs between B6, B6.Sst1<sup>S</sup>, and Sp140<sup>‚Äì/‚Äì</sup> mice. Elevated type I interferon levels in Sp140<sup>‚Äì/‚Äì</sup> mice during <italic>M. tuberculosis</italic> infection were confirmed by RT-qPCR (Figure 3A), and we confirmed the hypothesis that elevated type I interferon drove susceptibility of Sp140<sup>‚Äì/‚Äì</sup> mice by infecting Sp140<sup>‚Äì/‚Äì</sup> Ifnar<sup>‚Äì/‚Äì</sup> mice. To further address the reviewer‚Äôs concern, we have also included new RT-qPCR data that confirms the elevated levels of the type 1 interferon stimulated gene Il1rn in our RNA-seq data for B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice (Figure 4 ‚àí figure supplement 1). Because of batch effects, and experiment-to-experiment variability in in vivo lung infections, adding an additional replicate is not straightforward. We do not believe that additional RNAseq replicates would change the conclusions of our paper or even provide further significant insights into the phenotype.</p><disp-quote content-type="editor-comment"><p>5) The authors mention that they did not observe a consistent difference between the Sp140-/- and Sst1S mice, however, these strains are not completely overlapping in the expression profiling analysis. This could be because Sst1S has some expression of Sp140, whereas the KO has none, but this should be discussed. It would also be helpful to include WT B6 in the heatmaps in 4C and D.</p></disp-quote><p>We agree with the reviewers and have expanded our discussion of the transcriptional differences between B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice in the text (lines 263-268). We do not expect B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice to be transcriptionally identical, due to the loss of expression of Sp110 in B6.Sst1<sup>S</sup> mice and possibly additional background or microbiota differences. However, as we state in our paper, our analysis shows that these mice show highly similar transcriptional responses to <italic>M. tuberculosis</italic> infection. The B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> samples clearly cluster together along the PC1 axis in Figure 4A, which account for 77% of the variance in our RNA-seq data, and only separate for PC2, which accounts for only 9% of the variance in our data (lines 234-235). These samples also cluster together in Figure 4B, and in Figure 4E we show that differentially expressed genes between B6.Sst1<sup>S</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice during <italic>M. tuberculosis</italic> infection are of relatively moderate significance, with the expected exception of Sp110. Again, our conclusion is not that Sp140<sup>‚Äì/‚Äì</sup> mice are identical to B6.Sst1<sup>s</sup> mice, but rather that Sp140 deficiency is responsible for the type I IFN-driven susceptibility to bacterial infection in B6.Sst1<sup>S</sup> mice. The heatmaps in 4C and 4D display fold change relative to infected WT B6, which is now clarified in the figure legend, so showing this condition would not be informative.</p><disp-quote content-type="editor-comment"><p>6) In Figure 2, the levels of Sp140 protein in the Sp110-/- mice should be included in panel B to show that protein expression is intact (not just transcript) to rule out epistatic effects of missing both Sp140 and Sp110.</p></disp-quote><p>Although we agree that understanding the relative contributions of Sp110 and Sp140 is important, we do not understand the reasoning behind the experiment the reviewers suggest or what potential &quot;epistatic effects&quot; the reviewers have in mind. Note that we find that Sp110<sup>‚Äì/‚Äì</sup> exhibit wild-type resistance to infection. If Sp140 protein expression is ablated in Sp110<sup>‚Äì/‚Äì</sup> mice, we would predict the mice would phenocopy the susceptibility of B6.Sst1<sup>S</sup> mice, which lack both Sp140 and Sp110. In other words, we fail to understand how Sp140 would be epistatic to Sp110 (i.e., how would loss of Sp140 obscure the phenotype of Sp110 deficiency?) since we know that loss of Sp140 alone (or in combination with loss of Sp110) results in susceptibility to infection. One interesting possibility might be that upregulation of Sp140 in Sp110<sup>‚Äì/‚Äì</sup> mice could explain their resistance to bacterial infection. However, from our RNA-seq analysis, we observe very minor changes in transcript levels of Sp140 in our Sp110<sup>‚Äì/‚Äì</sup> mice during <italic>M. tuberculosis</italic> infection relative to B6. We have added an additional supplement showing the expression of SP family members (Sp100, Sp110, Sp140) in both Sp110<sup>‚Äì/‚Äì</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice (Figure 4‚Äîfigure supplement 2; lines 249-258). We found that there is no significant difference in the levels of Sp100 in Sp110<sup>‚Äì/‚Äì</sup> mice compared to B6 or B6.Sst1<sup>S</sup>. If anything, we observed a small decrease (rather than increase) in the expression of Sp140 in Sp110<sup>‚Äì/‚Äì</sup> mice relative to B6 mice, but this change in Sp110<sup>‚Äì/‚Äì</sup> mice is less than 2-fold and has a relatively high adjusted p-value (0.0343). Conversely, Sp140 is significantly upregulated in Sp110<sup>‚Äì/‚Äì</sup> mice compared to B6.Sst1<sup>S</sup> mice (fold change = 3.3849, adjusted p-value =1.49E-14 ). Overall, we do not observe major changes in the expression of other SP family members in Sp110<sup>‚Äì/‚Äì</sup> and Sp140<sup>‚Äì/‚Äì</sup> mice. Therefore, we believe that the targeting of these genes had specific rather than unanticipated epistatic effects.</p><p>In our view, however, the key experiment is to ensure that SP110 protein is present in Sp140<sup>‚Äì/‚Äì</sup> mice, which are susceptible to bacterial infection. This experiment is important to rule out any effects of the loss of Sp140 on Sp110 expression, and to demonstrate that Sp110 is not sufficient to protect against bacterial infection. We show normal SP110 expression in Sp140<sup>‚Äì/‚Äì</sup> macrophages in Figure 2‚Äîfigure supplement 1D.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>In this manuscript, the authors build off their previous data where they have identified differences in the sst1 locus as responsible for differences in susceptibility of B6 and C3HeB/Fej mice to Mycobacterium tuberculosis infection. The authors have previously shown that this susceptibility is attributed to higher levels of type I IFN signaling and in particular, the ISG IL-1Ra. The sst1 locus contains many genes that could be contributing to the differential susceptibility in C3HeB/Fej mice, and the model in the field was that differences in Sp110 expression was a likely candidate to explain the susceptibility. However, in this manuscript, the authors show that it is not lower expression of Sp110, but instead decreased expression of another gene in the sst1 locus, Sp140, that contributes to the increased susceptibility of mice carrying the sst1S sequence to bacterial infections. This is a very significant and surprising finding, supported by very clear and convincing data from experiments performed with a high level of rigor. Although identification of the gene responsible for differences in susceptibility and outcomes during bacterial infections is an advance for the field, the manuscript stops there in terms of new insight and falls short of providing any additional information beyond what has already been published regarding how this gene or lucus is functioning to regulate immune responses to infection. This limited scope embodies the major concern for this otherwise strong manuscript.</p></disp-quote><p>We thank for the reviewer for recognizing the importance of our discovery that loss of Sp140 (not Sp110) confers susceptibility to <italic>M. tuberculosis</italic>. Our generation of Sp140 deficient mice allows us to demonstrate, for the first time, that Sp140 is a negative regulator of type I IFNs. By generating crosses between Sp140<sup>‚Äì/‚Äì</sup> and Ifnar<sup>‚Äì/‚Äì</sup> mice, we further demonstrate that type I IFNs mediate the susceptibility of Sp140<sup>‚Äì/‚Äì</sup> mice to <italic>M. tuberculosis</italic> and Legionella. The reviewer appears to believe that because IFNs were previously shown to mediate the phenotype of Sst1<sup>S</sup> mice that somehow the function of Sp140 was already known. By contrast, we feel that in fact the function of Sp140 was not at all clear prior to our work, and that our work does indeed provide important mechanistic insight into the function of Sp140 as a regulator of type I IFNs. Sst1<sup>S</sup> mice contain many genetic differences compared to B6 mice. It is only because of our work that we can now go back and reinterpret the prior work on Sst1<sup>S</sup> mice, but this would not be possible without the work we have reported in this paper. Of course we would love to be able to describe more about the molecular mechanism by which Sp140 represses interferon transcription. This is indeed something we are working on. However, our preliminary experiments indicate this is not likely to be straightforward and will require considerable effort that is certainly beyond the scope of this current paper. It should be noted, for example, that Sp140 is in the same protein family as the well-known transcriptional regulator Aire. The mechanism by which Aire regulates gene expression has been studied for almost two decades and is still not entirely clear (and was certainly not clear in the initial foundational paper on Aire function published by Anderson et al. in Science in 2002). We expect the mechanism of Sp140 to be similarly complex. Importantly, we now know for the first time which protein to study mechanistically, i.e., SP140 instead of SP110.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:The authors have suggested the importance of SP140 for resistance to Mtb, Legionella infections in mice. They also provide evidence for IFNaR signalling in mediating the increased susceptibility of SP140-/- mice. While they attribute an important function of the transcriptional regulator SP140 to regulation of type I IFN responses by demonstrating the dysregulation of these responses in the SP140-/- mice, more direct evidence for this is needed.</p></disp-quote><p>We appreciate the reviewer‚Äôs succinct summary of the main conclusions of our manuscript. While we would agree that there is more to learn about the mechanism of SP140 function, it is not entirely clear to us what the reviewer means when they say that more ‚Äúdirect‚Äù evidence is needed for our claim that Sp140 regulates the IFN response during bacterial infection. We feel that the genetic experiments we provide are clear on this point. The reviewer may be thinking that we are proposing a specific mechanism, e.g., that our model is that Sp140 regulates IFN production by binding to the IFN Œ≤ gene; although that is an appealing possibility, we agree that is not shown in our manuscript, and indeed, we are careful not to make any such claim. Indeed, we explicitly state that a more indirect mechanism is possible (line 390). What is clear, though, is that loss of Sp140 mediates susceptibility to infection via (direct or indirect) increases in type I IFN. We observe increased type I IFN responses in Sp140<sup>‚Äì/‚Äì</sup> mice in vivo, and moreover, we find that a cross of Sp140<sup>‚Äì/‚Äì</sup> mice to Ifnar<sup>‚Äì/‚Äì</sup> mice reverses susceptibility to infection. These results demonstrate that the dysregulation of type 1 IFN in the absence of Sp140 is not merely correlative, but in fact drives susceptibility to bacterial infection in vivo.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>In this manuscript Ji et al. carefully examine candidate genes driving a previously described susceptibility within the severe susceptibility to tuberculosis (sst1). Surprisingly, mice deficient in the original candidate gene within this locus, SP110, showed no change in susceptibility to infection with M. tuberculosis. In contrast, the authors found that loss of a second gene in this locus, SP140, recapitulated many phenotypes seen in the SST1 mouse, including increased Type I IFN. SP140 susceptibility was reversed by blocking these exacerbated type I IFNs, similar to SST1 mice. RNAseq analysis identify changes in pro-inflammatory cytokines and type I IFNs. The strengths of this paper are the careful and controlled experiments to target and analyze mouse mutants within a notoriously challenging region with homopolymers. Their results are robust, convincing and will be of broad interest to the field of immunology and host-pathogen interactions. Convincingly identifying a single gene within this region that recapitulates many aspects of the SST1 mouse is very important. While a minor weakness is the lack of any mechanistic understanding of how SP140 functions, this is overcome by the impact of the other findings and it is anticipated that this mouse will now be a key resource to dissect the mechanisms of susceptibility in much greater detail.</p></disp-quote><p>We thank the reviewer for their generous evaluation. Mechanistically, we do show that Sp140 affects resistance to bacterial infection via regulation of the interferon response, which we think is an important and technically non-trivial advance that provides insight into the function of Sp140. However, we agree that the mechanism for how Sp140 regulates type I IFN is not shown (nor is it claimed to be shown) and addressing this mechanism is now an important and exciting question for future studies.</p></body></sub-article></article>